Hostname: page-component-5f7774ffb-mstw7 Total loading time: 0 Render date: 2026-02-19T14:08:30.879Z Has data issue: false hasContentIssue false

A Just Transgression of AMR Governance? How Mexico City’s Informal Medicine Sellers Balance Antibiotic Care and Control by Bending the Rules

Published online by Cambridge University Press:  19 February 2026

Rodrigo Rangel-Gutiérrez
Affiliation:
1Department of Anthropology, University of Amsterdam , The Netherlands 2Department of Anthropology, University of California Berkeley, USA
René Gerrets*
Affiliation:
1Department of Anthropology, University of Amsterdam , The Netherlands 3Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam University Medical Center, University of Amsterdam, The Netherlands
*
Corresponding author: René Gerrets; Email: r.p.m.gerrets@uva.nl
Rights & Permissions [Opens in a new window]

Abstract

This article explores how informal medicine sellers (IMSs) in Mexico City “contest” and “reassemble” antibiotic control standards in ways that both challenge and respond to antimicrobial resistance (AMR) governance. Drawing on ethnographic fieldwork, we examine the “rationales”—moral, political, economic, technoscientific, and practical—that IMSs invoke to justify bypassing antibiotic prescription, dispensing and accounting regulations, and the “practical tinkering” they perform to make antibiotics available and “appropriately” used under conditions of scarcity and oversight failure. Rather than viewing IMSs as simply breaking official rules, we adopt a “social life of standards” perspective to argue that their actions reflect localized enactments of antibiotic control—versions shaped by community needs, corruption, poverty, and distrust in public health infrastructures. These practices are ambivalent, blurring boundaries between public service and profit and systemic subversion and informal regulation. By tracking how IMSs adapt, collectivize, and sometimes deliver treatments, we show how antibiotic governance is reworked from below—not only in response to AMR, but also to structural exclusions from formal care. We argue that rather than treating IMS rationales and practices as part of the problem, they should be studied as grounded responses to systemic failure—and potential sources of insight for context-sensitive regulatory design.

Information

Type
Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press

Informal medicine sellers (IMSs) occupy a strategic, yet ambivalent position in the fight against antimicrobial resistance (AMR). In many low- and middle-income countries, they increase the accessibility and affordability of lifesaving medicines, provide trusted, sometimes-first-response care, and frequently make up for public health system dysfunction.Footnote 1 Yet, working informally—outside strict official oversight and often without requisite qualifications—IMSs are associated with nonprescription antibiotic dispensing, considered a driver of inappropriate antibiotic use and AMR.Footnote 2 This ambivalence poses a dilemma for AMR responses: cracking down on IMSs may seem an effective measure to regulate antibiotic consumption more strictly, but it may also reduce antibiotic access for populations lacking equitable access, potentially causing more harm than good.Footnote 3

IMSs in Mexico City illustrate this tension. Research directly examining Mexico’s informal pharmaceutical trade remains scant.Footnote 4 However, recent journalistic reporting suggests that IMSs helped meet demand left by medicine shortages and coverage interruptions resulting from poorly planned health system reforms.Footnote 5 Yet, the very existence of IMSs—working in unregistered outlets, routinely bypassing antibiotic dispensing standards—challenges regulations established to combat AMR.Footnote 6 Nevertheless, given that they may both (a) increase access to antibiotics amid public pharmaceutical shortages and (b) make them more affordable amid a prolonged economic downturn and increasing health expenditures, their ambivalence persists.Footnote 7

AMR, a serious public health threat in Mexico, has attracted significant regulatory attention. In 2019, approximately 70,100 people died from AMR-related causes.Footnote 8 In 2010, Mexico’s Ministry of Health made prescriptions for antibiotics mandatory, to reduce “… self-prescription, inappropriate use and the development of resistance.”Footnote 9 In 2018, COFEPRIS (Mexico’s national medicines authority) and a “committee of experts” introduced the “Control of Antibiotics” framework.Footnote 10 These regulations for pharmaceutical outlets aimed to strengthen the 2010 prescription requirement by imposing standard procedures on dispensing, including registering and keeping antibiotic prescriptions for audit purposes.Footnote 11 Yet, conditions at street level suggest significant implementation obstacles.

Cori Hayden has highlighted the longstanding practical absence of pharmaceutical regulation in Mexico City’s barrios—as one informant stated “… anyone can open a pharmacy, anywhere!”Footnote 12 This reported free-for-all pharmaceutical economy suggests that many unregistered pharmaceutical outlets are “invisible” to the authorities, rendering prescription audits practically impossible and associated regulations, “paper tigers.”Footnote 13 Indeed, the existence of medicine street markets reflects significant oversight gaps in Mexico City and the diverse shapes informal pharmaceutical commerce can take.Footnote 14 Ultimately, this situation indicates that total enforcement of antibiotic control regulations would require a clampdown on any and every commercial pharmaceutical outlet.

Suggesting a middle ground, recent scholarship shows growing support for building alliances with retail-level actors to optimize antimicrobial dispensing and use within communities.Footnote 15 Educational interventions, key to creating these alliances, have yielded positive results, yet also have drawbacks: bringing community-level actors’ practices closer to the norm without understanding and integrating what works for them risks sidelining their context-specific know-how.Footnote 16 Furthermore, as educational interventions gained popularity, few have questioned whether what is deemed appropriate from a regulatory standpoint is practically and financially feasible for IMSs: whether behavioral approaches can overcome structural barriers, if what is appropriate from above is appropriate at street level, and if care sometimes means amending or bypassing standards and regulations.Footnote 17

Our article builds on ethnographic fieldwork and semistructured interviews with IMSs in Mexico City to explore this problem-space. Adopting a “social life of standards” perspective, we explain the “rationales” IMSs invoke to justify their informal practices.Footnote 18 We present them non-normatively, while acknowledging their “ambivalence”: sellers blur the line between acting as a public health resource in an underperforming system and running a private business in a permissive regulatory environment.Footnote 19 Then, we show that through their antibiotic-centered practices, they do not simply break rules. Rather, IMSs “reassemble” antibiotic control standards into versions that fit their livelihoods and communities’ needs.Footnote 20 To conclude, we emphasize that corruption and inequalities in access to healthcare, and top-down regulations that ignore these realities generate a healthcare landscape where rule-bending becomes a moral imperative.

1. Theoretical background

1.1. The entwinements and ambivalences of informality

The concept of “informality” draws analytical attention to modes of social organization and practice that differ from official bureaucratic requirements, such as legislation and regulation, in contexts where similar activities or social formations typically comply.Footnote 21 Phenomena classified as “informal” are generally understood to be (a) pragmatic and makeshift rather than rationalized or systematically planned and organized following preset principles; (b) unwritten, unregistered, or lacking formal representation; and (c) semiclandestine, existing outside state-backed legitimacy or in defiance of established rules.Footnote 22

Despite their binarism, however, formality and informality have long been understood as intertwined, co-constituted, and mutually dependent.Footnote 23 With the institutionalization of every new rule, law, procedure, or standard, arises a possibility—and sometimes an incentive—to bypass or break it.Footnote 24 Substantial scholarship examines how formal structures are made to work informally, and vice versa. Footnote 25 These entwinements hint at a formal-to-informal continuum rather than a dichotomy, with context-bound dynamics.Footnote 26

An additional layer of complexity is the “ambivalence” of informal practices, which operate with “double standard,” “double deed,” and “double incentive.”Footnote 27 Such logics underlie informal practices and ways of communicating them.Footnote 28 Herein, we highlight three types: (1) “normative,” where a practitioner’s identity shapes a practice’s morality, (2) “functional,” where bypassing systemic obstacles to access specific resources both subverts and supports formal structures; and (3) “motivational,” where practices seem driven by both public and private interests.Footnote 29

Understanding the informality of IMSs from this perspective allows us to acknowledge them as self-interested economic actors in unregulated—but sometimes necessary—markets, who are also deeply embedded in their communities and oftentimes invested in their care. This perspective, thus, enriches previous portrayals that tended to represent them as primarily one or the other.Footnote 30 Fundamental to our analysis is that “[in]formality is grounded in the human ability to justify subverting constraints,” often through appeals to context-specific exceptionality such as friendship or necessity.Footnote 31

In the following subsection, we explain our treatment of the concept of ‘rationale’ as a particular expression of situated reasoning used to justify contextualized pharmaceutical practices, in contrast to official ‘rationality.’

1.2. Official rationality, rationales, and antibiotic-centered practices

The “rational use of drugs” has been defined as a “dominant normative framework” that prescribes and justifies promoting “… the judicious prescription by well-informed professionals of well-studied drugs to well-informed patients for well-defined conditions.”Footnote 32 Its corollary—practices that deviate from this are irrational—has been criticized for limiting understanding of real-world pharmaceutical consumption and prescription practices, including underlying “rationales” shaped by “… individual and local logics, representations, incentives, and constraints….”Footnote 33 Furthermore, “irrationality” has been criticized for characterizing populations in the Global South as composed of “deficient” subjects whose “misbehavior” and lack of appropriate knowledge, expressed in their use of antibiotics, must be managed.Footnote 34 The term “rationale” highlights the situated reasoning that informs antibiotic-centered practices that deviate from the officially ‘rational’ or ‘appropriate’.Footnote 35

A growing body of literature explores why health professionals and patients stray from clinical guidelines, antibiotic regulations, and prescriptions.Footnote 36 Among prescribers, adjusting to patients’ treatment-seeking behavior and practical constraints (e.g., staff shortages or time constraints) are common justifications.Footnote 37 Health professionals have expressed criticism of top-down antibiotic policies without context-sensitive adjustments and attention to systemic issues.Footnote 38 Among patient rationales for antibiotic use, Rodrigues found that familiarity with typical uses of certain antibiotics, repetition and adjustment of previously prescribed treatments, and advice from dispensers or the internet often shaped patients’ situated reasoning.Footnote 39 Primarily explored among prescribers and patients, the term “rationale” thus encompasses moral, political, economic, technoscientific, and practical judgments grounded in empirical knowledge.

Research examining rationales that IMSs hold for challenging antibiotic regulations is limited and skewed in two ways. Firstly, IMSs are mainly portrayed as driven by economic or social motives, without being credited with the capacity to reflect on their ambivalent positions providing care-for-profit in the unregulated sector.Footnote 40 Secondly, widespread findings of limited knowledge about antibiotics and regulations among community-level healthcare providers may have discouraged deeper inquiry into their views on specific regulatory items like prescription requirements.Footnote 41

However, Álvarez’s journalistic account from a Mexican street market suggested such an investigation was possible: an IMS reported that their medicines were not and could not have been stolen from public institutions because the health sector suffered shortages of those medicines.Footnote 42 Another seller mentioned keeping medicines in the shade.Footnote 43 These accounts signaled two insights: (1) that medicine sellers were capable of critiquing public healthcare, legitimizing their products and practices and (2) that while pharmaceutical risks could be framed as “science-driven scenarios,” they were also proximate, everyday concerns.Footnote 44 Concretely, keeping medicines in the shade suggested a rudimentary attempt to prevent environmental conditions from degrading medicines.Footnote 45 Álvarez’s account of IMSs’ informal practices, including local adaptations of official standards, informed this research and its central analytic themes.

1.3. Tinkering-with and reassembling standards

Standards and technical regulations can be thought of as rules, usually codified or formally represented, that apply to both things and people.Footnote 46 “They are crucial to the regulation of safe and effective technologies and key for the legitimization of evidence and expertise.”Footnote 47 They are often presented as “universal” and grounded in scientific evidence and paraphernalia to bolster their authority.Footnote 48 In practice, however, their universality runs into context-specific implementation obstacles.Footnote 49

When this happens, “practical tinkering” becomes necessary to adjust situated practice to the standard and vice versa. Footnote 50 Recent scholarship on “the social life of standards” explores how these sociomaterial rules are adapted and localized beyond the imagined, perfectly fitting spaces where they are supposed to be implemented.Footnote 51 Depending on how standards are put in practice relative to their original schematic form, invoking Graham et al.’s analytic vocabulary, standards are “subverted,” when they are “… covertly … manipulated so that they can continue within power discourses while being adapted for the local context,” and “contested,” when they are “subjected to overt political conflict … [and] overtly disrupted.”Footnote 52

Because standards exist on paper and are enacted in objects and practices, they can be “reassembled” in two ways.Footnote 53 Whereas Graham et al. generally use the term to signal processes of modifying standards as texts or schematic forms through legal procedures, we draw on Busch and Suzuki, who suggest that “practical tinkering” generates enactments that change the “script,” much like when actors improvise dialogue.Footnote 54 Through this process, standards become “localized” into specific environments and undergo a ‘practical reassemblage.’Footnote 55

This study contributes to these discussions by studying how IMSs’ antibiotic-centered practices represent localized enactments of official antibiotic control standards, adapted to fit marginal urban contexts and legitimized by local rationales contesting their official versions. By adopting this perspective, we do not suggest that IMS practices are always similarly effective at mitigating public health risks as fully compliant pharmaceutical practice is. Indeed, we highlight key ambivalences and potential risks. However, we emphasize that, despite lacking formal training, IMSs can use their experience and knowledge to generate their own regulatory forms, which can serve to inform context-sensitive policy interventions.

In the next sections, we outline the socioeconomic and healthcare context of Mexico City’s informal care market and the methods used in this study.

2. Setting

The Mexico City Metropolitan Area (MCMA) encompasses approximately 21.8 million people living in Mexico City proper and the adjacent urban sprawl of small cities and semirural settlements.Footnote 56 The region’s healthcare landscape reflects the plurality, fragmentation, and systemic exclusions of Mexico’s national health system.Footnote 57

The MCMA contains major public hospitals and clinics (many with attached pharmacies), private hospitals and practices, and numerous private pharmacies, some with annexed consultation rooms.Footnote 58 Historically, formal employees in the public and private sectors with “contributive” social security have been prioritized, leaving millions of residents without employment-based social security with unequal access to formal healthcare.Footnote 59 Instead, they depend on “public charity,” remedial universal coverage schemes, and the private sector for healthcare.Footnote 60 Additionally, shortcomings affecting the public system make private care increasingly attractive to insured patients.Footnote 61

Hence, as Osorio and Hayden reported, pharmacies with consultation rooms—particularly generics pharmacies—have become a crucial, low-cost alternative to public primary care.Footnote 62 “Mom-and-pop” medicine shops—with and without consultation rooms—offer livelihood opportunities to small-scale entrepreneurs, retirees, medical students awaiting diplomas, and underemployed physicians.Footnote 63 However, despite their importance as health resources and livelihood strategies, pharmacies-with-consultation-rooms have been criticized for ‘promoting inequity’ because they depend on patients’ out-of-pocket spending and the state’s failure to provide high-quality, reliable, universal healthcare.Footnote 64

This public–private mixture of providers has made “contributive” social security coverage or the “capacity-to-pay” key barriers to accessing healthcare, especially since recent system-wide reforms.Footnote 65 Nationwide, between 2018 and 2024, the number of people lacking access to public healthcare nearly doubled to more than 44 million.Footnote 66 This coincided with the dismantling of Seguro Popular—a universal coverage scheme created in 2003 for those without contributive social security.Footnote 67 Over the same period, households’ out-of-pocket health expenditures increased by 41.4% nationwide, largely due to the doubling of household spending on medicines.Footnote 68 These increases coincided with efforts to centralize public pharmaceutical procurement and distribution—a process that, alongside the COVID-19 pandemic, exacerbated medicine shortages across the country.Footnote 69 These broader developments influenced the MCMA’s informal healthcare market. Reduced access to public medical care and widespread medicine shortages have reportedly stimulated demand for pharmaceuticals in the so-called “black market.”Footnote 70

Despite being understudied, the region’s informal healthcare market includes forms of pharmaceutical commerce beyond ‘mom-and-pop’ drug shops, namely in food markets and street markets.Footnote 71 Although these outlets may share similarities with informal pharmacies, the absence of consultation rooms and on-site physicians generates greater variability in, and concerns about, the quality of their services and products.Footnote 72 Faltering medical and regulatory oversight can explain reports of them selling controlled pharmaceuticals, including antibiotics, without medical prescriptions.Footnote 73

3. Methods

This article draws on two months of ethnographic fieldwork conducted across various informal pharmaceutical outlets (i.e. not registered with COFEPRIS) across the MCMA. Our methodological approach built on RRG’s pre-existing social ties with the participants and background knowledge of their workplaces, as a native of Mexico City with family ties to the informal economy. Given the semiclandestine nature of this trade, recruitment relied on personal networks, street canvassing, and snowball sampling. The main inclusion criteria were that participants were adults (18+) involved in operating informal pharmaceutical outlets (IMSs and helpers) or in supplying medicines to an IMS (suppliers).

Fieldwork began in the public food market of La Merced (central Mexico City), and the street market of El Salado, east of the city. Using a “follow the medicine” approach, we identified other actors, places, and processes involved in the circulation of pharmaceuticals.Footnote 74 This ‘revealed’ additional street markets and unlicensed pharmacies, and customers, medicine sellers, and medical professionals who often acted as suppliers to informal pharmaceutical outlets. In total, five IMSs operating a total of 16 informal outlets, one helper, and two suppliers were included as core participants.

Two principal research techniques—‘deep hanging out’ and “go-alongs”—enabled sustained, everyday engagement with sellers as they sourced, stocked, and sold medicines, providing insight into their handling of pharmaceuticals, interpretation of regulatory issues, dealings with authorities, commercial strategies, and interactions with customers.Footnote 75 They also provided insight into the routines of the helper and suppliers. Data collection included detailed fieldnotes from participant observation and informal conversations, and audio-recorded semistructured interviews exploring how participants navigated obtaining, transporting, storing, prescribing, selling, licensing, and disposing of medicines. Long hours in each outlet facilitated informal conversations with customers and brief interviews with actors shaping the local care ecosystem, including one medicine seller who did not want to be recorded but answered some questions via text message and a doctor who answered questions by phone. These exchanges contextualized participants’ narratives and practices. Research additionally included a review of key regulatory documents, such as Mexico’s General Law of Health and the Pharmacopoeia’s Supplement for medicine-selling establishments, to contrast formal expectations with street-level practices.Footnote 76

Interviews were conducted in Spanish and later translated with attention to tone and context. Data were thematically analyzed using an “inductive and deductive” approach.Footnote 77 Ethical protocols included pseudonymization of all names and maintaining ongoing informed consent.

In the following sections, we draw on the cases of Marcelo and Sergio—two cousins in a family that has adopted pharmaceutical commerce as the family business. Marcelo, in his late 50s, studied Communication, and was the family’s first pharmaceutical entrepreneur.Footnote 78 He built a small empire of unlicensed drug shops in the outskirts of the city and introduced his brothers and cousins to the trade.Footnote 79 Sergio, a few years younger, was a potato seller in the city center before becoming a medicine seller.Footnote 80 He entered the business after Marcelo attempted to set up a small “pharmacy” in the stall next to his and abandoned it due to low returns.Footnote 81 Left with Marcelo’s remaining stock, Sergio kept the business going by sourcing medicines at his cousin’s usual suppliers.Footnote 82 At the time of this study, their businesses were already established and operated independently.

We begin by examining Marcelo’s critiques of antibiotic regulations and analyze the ambivalences embedded in the rationales he presents as justifications to bypass them. Then, we follow Sergio and his helper Gloria’s work in the food market of La Merced, where they adapt antibiotic-related standards to local beliefs, financial constraints, and healthcare access limitations.

4. Contesting antibiotic control in the street

In 2024, Marcelo had almost 20 years of experience in the business.Footnote 83 He had set up each of his drug shops himself, adapting the space, tending the counter, hiring personnel, and eventually transitioning into more of a managerial and administrative role—except for his main shop, which operated out of a couple of storefronts annexed to his house.Footnote 84 Marcelo occasionally worked the counter and used his main establishment to test business ideas, such as a naturist medicine and supplement shop, which he established in a storefront that had previously housed an annexed consultation room, where he had employed several doctors over the years (see Section 2.).Footnote 85 However, around 2016, he moved away from employing doctors in his businesses.Footnote 86 By 2024, his six locations were standalone drug shops.Footnote 87

Marcelo holds himself and his employees to a “decalogue” of service standards, according to him, pasted near the counter of all his establishments.Footnote 88 The one in his main pharmacy had nine items, including “Always call [Marcelo] if we don’t have the medicine and ask if we can get it” or “If a client is missing 1, 2 or 3 pesos to buy their product, tell them don’t worry they can leave it later” (see Figure 1).Footnote 89 In his words: “… to be a pharmacist is a great commitment—like [Spiderman’s] Uncle Ben would say—‘with great power comes great responsibility’.”Footnote 90

Figure 1. Marcelo’s customer service decalogue. Digital photo by RRG, unlicensed pharmacy in the outskirts of Mexico City, April 16, 2024.

Marcelo had his own standards surrounding antibiotics too. Despite bypassing most antibiotic control regulations, selling them “indiscriminately,” he could explain why this was and should be the case.Footnote 91 His rationales were complex and layered, embedded in the context where his pharmacies operated and grounded in his experience working the counter. We present them in the order of importance Marcelo gave them.

4.1. Corruption makes antibiotic regulations just tools for extortion

Marcelo seemed to hold 2018’s Control of Antibiotics regulations in special contempt, and his rationale to bypass them was that they provided government inspectors just another avenue to extort his business.

Regulations mandate that pharmacy audits are conducted by COFEPRIS or state health authorities to check for integral compliance with pharmaceutical outlet regulations.Footnote 92 In Marcelo’s experience, however, inspectors primarily used these audits to make a quick buck by identifying or making up irregularities and asking for payoffs so establishments could get off the hook. Actual compliance with regulations, he reported, was of secondary importance: “If they feel like it, you won’t pass.”Footnote 93 Thus, Marcelo described that Control of Antibiotics regulations, in practice, was just an instrument for predatory government employees to extract “tolls.”Footnote 94

… you’re supposed to keep a record of medications like an accountant, but that book is just so that COFEPRIS knows how you’re managing antibiotics … How many antibiotics came in? How many went out? How many with a prescription? …

—And how do you handle that? [RRG]

—Well, you don’t do anything. … Everything gets handled once the COFEPRIS guy shows up. … Pay them, and if someone else comes by for an inspection, you tell them: “the other guy already came—nothing to worry about.” . … They measure everything. Literally everything. … And things that don’t fall under their scope. … [COFEPRIS inspectors] come for their yearly or semiannual fee. … They’ll find a way to mess with you. Or maybe they won’t. … Why risk it? They take 5,000 pesos [US$260] from me every two or six months. … Now they just show up all cheeky and say, “How are we doing? Six months have passed. Time flies, right?” And they’ll want to raise the fee. It’s extortion.Footnote 95

Although Marcelo called these transactions “extortions,” they seemed to allow his pharmacy empire to continue operating despite its minimal compliance with regulations. Interpreted from the perspective of state visibility, two layers of concealment enabled Marcelo’s business.Footnote 96 One was his lacking registration with COFEPRIS, reducing chances his establishments appeared on the authorities’ radar; the other involved inspectors’ discretionary practices, which invisibilized his spotted establishments from COFEPRIS to hold them hostage and continuously extract a toll so routinized and brazenly requested that Marcelo called it a “fee.”

According to Marcelo’s account, what were basically pharmacy requisites for “antibiotic accounting,” and other regulations became “subverted” by these informal transactions.Footnote 97 They allowed inspectors to enrich themselves in exchange for helping Marcelo conceal his noncompliance, and for the business to continue as usual, as if regulations had been implemented.

The transaction described above is marked by “motivational” and “normative ambivalence,” because Marcelo participated in—and benefitted from—an act he dubbed inspectors’ abusive behavior and coercion, omitting his possible collusion therein.Footnote 98 Regardless of how Marcelo actually participated in these transactions, analyzing them as his rationale to bypass burdensome requisites reveals a situated, informal logic. If, as Marcelo says, inspectors do not check for compliance or are willing to make up violations, prescription registering and antibiotic accounting are pointless activities.

4.2. The prescription requirement unnecessarily excludes the poor from buying antibiotics

Marcelo’s rationale to bypass the prescription requirement was that it ignored conditions at street level, limiting access to antibiotics without actually optimizing their use in the public.Footnote 99 His critique and efforts to practically amend it showed that Marcelo understood and accepted the risk these regulations aimed to mitigate—AMR—but contested and adapted the mechanism through which they intended to act.

Sometimes governments do things … without understanding the people in that milieu. They do it at scale, from above. … They launched their law and said… “you can’t sell antibiotics because people are becoming resistant to them, because they buy them without a prescription.” … False! The problem [is when] … a doctor sends you five ampicillin injections … which should end your problem. At the second one, you feel better already and say, “Oh, it hurts, I’m not getting the third one.” You don’t finish the treatment, so … the bacteria grow resistant to the medicine, so then when you give it ampicillin again, you say, “it won’t do anything”. What’s happened is the bacteria have vaccinated themselves against the antibiotic, too. It’s a natural process common to all living beings. I protect myself, too.Footnote 100

A deep distrust of the state’s capacity to understand the problem at a basic scientific level informed Marcelo’s contesting of the prescription requirement. Even though Control of Antibiotics regulations in Mexico do not operate with the mischaracterization Marcelo described (that people become resistant to antibiotics), some confusion did attend the initial rollout of the prescription requirement. The then-head of COFEPRIS declared in a newspaper that “… people that take antibiotics become immune and resistant towards bacteria they did not have ….”Footnote 101 Marcelo’s skepticism extended into explicitly contesting the measures the government had taken, placing the responsibility on pharmacies to regulate the flow of antibiotics into the public instead of making doctors “conscientize” patients on how to properly use them.Footnote 102

Ultimately, for Marcelo, it was not access to antibiotics which had to be regulated, but their use. This form of blame-shifting toward consumers has been a common fixture of AMR-related initiatives.Footnote 103 Marcelo partially reproduced it and limited his responsibility to promoting more rational antibiotic use.

When … I was at the counter, I told them: “You’re going to feel better after the first or second [dose] but don’t interrupt the treatment because these medicines are already very strong. Imagine that after this you have to go to the hospital because you won’t be able to get better at home.” So, then it’s about making people conscious about what they’re taking and why they’re taking it.Footnote 104

For Marcelo, the prescription requirement seemed to be overkill, which he corrected by selling antibiotics without a prescription but reminding his customers to finish their treatments: his own “contested” version of antibiotic control.Footnote 105 Reminding people to adhere to their treatments mimicked standard pharmaceutical deontology, which includes promoting rational use, but differed from it in two crucial ways.Footnote 106 Firstly, he sold antibiotics without requesting a medical prescription, and secondly, he recommended antibiotic courses himself.Footnote 107 At play was a complex layering of ethical-economic reasoning and self-ascribed lay expertise (addressed in the following section).

The prescription requirement did not consider the financial limitations of his clientele, Marcelo explained, which his version of antibiotic control did: “The problem is not that I indiscriminately sell antibiotics. That’s actually super good, because a lot of people don’t have the resources to go to the doctor. Either they go to the doctor or they fill a prescription. So that’s my excuse.”Footnote 108

Thus, Marcelo’s rationale and his version of antibiotic control cast his indiscriminate antibiotic selling as a public service. He simultaneously undermined and complemented the formal healthcare system by violating its regulations and making up for its shortcomings. By reminding people to finish their treatments without checking if they actually had medical prescriptions, Marcelo (1) did his share of risk communication; (2) gave patients access to antibiotics without forcing them to provide proof that they had incurred expenses to see a doctor; and (3) removed a commercial barrier for his business. Marcelo’s “contested” version of antibiotic control, then, was functionally and motivationally ambivalent.Footnote 109

His rationale gains weight considering the broader healthcare context in Mexico, where out-of-pocket spending on health has surged in recent years (see Section 2). One study, for instance, estimated a 20% nationwide increase in excessive health expenditures between 2018 and 2020, disproportionately affecting uninsured households and linked to the termination of Seguro Popular, reductions in the Ministry of Health’s budget, and COVID 19-related service disruptions in public facilities.Footnote 110 In this context, any opportunity to economize can help.

4.3. An experienced local medicine seller knows better than poorly trained doctors

A final rationale to bypass antibiotic regulations, key to his recommending practices, was that Marcelo considered that doctors were not that well trained in pharmacology. He reckoned that years of self-studying and experience at the counter had taught him how to adjust prescriptions. “They take a year [of pharmacology], or a semester at most.”Footnote 111

I really had to study [the PLM, a pharmaceutical reference manual] to be able to make recommendations. … Experience with other doctors [also helped]. … People started trusting me a lot … someone would come in who hadn’t found me [at the counter], go to the doctor and come back … I’d say: “I don’t like this [prescribed] medication.” I would switch it out. … I’d discreetly step into the [annexed] consulting room and tell the doctor, “Doc, … if you give [this medication] every 8 hours, you’re going to kill him.” … I was basically teaching the doctor at that point.Footnote 112

These recommendations eventually creeped into prescribing. When we met Marcelo, he was often occupied with the finances of his pharmacies, but a phone call with Sergio, his IMS cousin, revealed how his prescribing operated:

— Good morning mai … A lady just called me whose husband cut his hand. She forgot or lost track of it and fed him bacon. [Sergio]

— Son of a bitch. [Marcelo]

— So he says his hand feels heavy … I told him I don’t know but you who know more … What could you suggest? [Sergio]

— If he’s not allergic, give him ceftriaxone. [Marcelo]Footnote 113

Marcelo’s self-appraised lay-expertise, based on his familiarity with medicines and doctors, similar to what Rodrigues observed among patients self-prescribing antibiotics, served as a rationale to take prescribing into his own hands and bypass the prescription requirement.Footnote 114 In other words, the logic appeared to be why send them to a doctor when I know what they are going to prescribe? Of course, beliefs like those expressed in the phone call—that eating pork with an open wound can lead to infection—suggest these prescribing practices are shaped by criteria that differ from biomedical knowledge, which can lead to unnecessary antibiotic consumption.

This lay-expertise rationale had been elaborated by suggesting that in this outer area of Mexico City, resistance had developed and certain antibiotics had become ineffective. Some doctors, for Marcelo, neither recognized AMR nor adjusted their prescribing practices. To illustrate his point, Marcelo recalled what he used to tell a young doctor, a former employee in one of his pharmacies:

“Doctor … you’re coming from one of those so-called rural clinics where you did your internship, and all they have there is … a very basic stock of medicines. So, you learn with what you have. … Penprocillin, penicillin, ampicillin—the basics [that] don’t do anything for us [people in his area] anymore. We’re already well hardened.” … “You don’t go beyond penicillins.” … “We have amikacin, we have lincomycin.” … It worried me because of my business, you know? … The patient won’t get better, and they’ll have to come back. … It’s not because I want to rotate stock or push my products—it’s because she wasn’t doing her job well. She said: “Why would we drop a bomb on an ant?” “It’s not an ant, doctor! We’re already toughened up! That stuff doesn’t work anymore.”Footnote 115

Marcelo knew that pressuring the doctor he employed to diversify her prescribing aligned with his commercial interests. Bypassing the prescription requirement generated more demand for different medicines while reducing the risk of less-popular products expiring in his stock. Yet, he maintained that his actions were not motivated by “greed” but addressed a real “need” in his community: cheap access to antibiotics some doctors may not know to prescribe.Footnote 116

His assertion that in his area, certain antibiotics had stopped working because consumers were “hardened,” appeared to colloquialize his textbook explanation of resistance into an anthropocentric idiom that cast the bodies of his clients as the sites where resistance emerged, instead of bacteria. This subtle modification, a ‘rhetorical-technical tinkering,’ shaped his argumentation.Footnote 117 Since “… standards invoke the linguistic categories … we use to organize the world,” the shift between the official and colloquial definitions of “resistance” entailed the difference between some infections being resistant, begging case-by-case diagnosis, and all local bodies being hardened, raising suspicion of medical prescriptions unaligned with Marcelo’s “localized” standard treatments.Footnote 118 This move—perhaps a “use of ignorance” to justify his practices by drawing on a common misunderstanding—took “resistance” from being the main rationale behind Control of Antibiotics regulations to being Marcelo’s rationale to question medical expertise and adapt antibiotic control to his business’, and according to Marcelo, his community’s needs.Footnote 119

In the following section, we describe how Sergio put Marcelo’s contested version of antibiotic control into practice, by “tinkering” with prescriptions and treatment adherence promotion in the food market of La Merced, central Mexico City.Footnote 120

5. Reassembling antibiotic control in the produce section

Every week, Sergio spends hours taking a knife to small imperfections on his potatoes. Deeming this unnecessary, other potato sellers sometimes make fun of this. When the potatoes are clean, he assembles orders for long-standing clients, delivering them to their businesses across Mexico City, using public transport.Footnote 121 Since entering the medicines trade in 2017, Sergio has adapted his work routines and stall to sell medicines alongside potatoes (see Figure 2), fostering a local clientele.Footnote 122 Yet, Marcelo continues to be Sergio’s main source of pharmaceutical knowledge, apart from the internet.Footnote 123

Figure 2. Box with the legend Antibiotics of Mexico, the name of a generic medicines company, on top of sacks of potatoes. Digital photo by RRG, La Merced market in Mexico City, June 6, 2025.

Among Sergio’s highest-selling products are ceftriaxone injections, oxytetracycline lozenges, and ampicillin tablets—sometimes used as pre-emptive treatments by La Merced’s workers, usually vendors, their helpers, and load haulers who cannot generally afford sick days.Footnote 124

5.1. Standardizing treatments and collectivizing prescriptions

Like Marcelo, Sergio also sold antibiotics without a prescription, or at least a personalized prescription.Footnote 125 Sergio took the few prescriptions he came across, estimated what seemed like an average treatment, and then reused it for several patients.Footnote 126 Sergio’s stall neighbor Gloria’s experience taking antibiotics illustrates this practice. During a “wave of infections” in the market, in November and December of 2023, she got sick and saw a doctor.Footnote 127

Doctor Victor … sent me seven sets of dexamethasone and ceftriaxone. I had to apply them both at the same time. Because [the doctor] sent seven, Sergio told me “No, how can you even think about it? Seven is too strong! Three is enough”. “But the doctor said seven”. “No but it’s too strong, it will harm you, in your body”. So, I listened to him and only got three. And indeed, people came by and only had three in their prescription. I don’t know why I was sent seven.Footnote 128

Sergio’s “tinkering” with Gloria’s prescription was informed by previously encountered prescriptions and by Marcelo’s advice.Footnote 129 Gloria saw this process unfold. While not Sergio’s employee, they had established a close working relationship, a practice common among vendors in La Merced: Gloria occasionally helped Sergio open his stall or deliver medicines, and he helped her move heavy objects and close her stall in the evenings.Footnote 130 An additional perk was Gloria’s famously “good hand” for injections. Sergio sent her “patients” and Gloria charged 20 MXN ($1USD) per injection (see Figure 3).Footnote 131

Many customers requested ceftriaxone and dexamethasone, but also alcohol, syringes and cotton balls. … Few came with a prescription. Most [were] in bad shape. “What can you give me?”. [Sergio] would say “No, well it looks like you’re heading that way, your throat hurts, your body… you’re getting [an infection]. Take this”. [Sergio sold] them the package of ceftriaxone with dexamethasone and [cough] syrup, and the Graneodín [lozenges]. … It’s the prescription, he copies the prescriptions. … What they [prescribed] me, he gave everyone. But to me he said, “The prescriptions I’ve been brought have three, so why are you getting seven?”. And then he asked Marcelo, his cousin, the pharmaco-biological chemist [Marcelo studied Communication]: “Hey, why did Gloria get seven and everyone else got three?” “No, I don’t know, but tell her not to get seven. It’s too much. Three sets are enough”. … After that, people with symptoms came and [Sergio] said, “I recommend you this [Gloria’s now-modified treatment], because it’s … what they’re recommending.”Footnote 132

Figure 3. A freshly used syringe and the packaging of a ceftriaxone vial on Gloria’s table. Digital photo by RRG, La Merced market in Mexico City, February 24, 2024.

Gloria explained this practice by saying that “If one of us had gone to the doctor it meant others didn’t have to pay”—echoing Marcelo’s suggestion that dispensing antibiotics without a prescription helps customers reduce their health expenditures.Footnote 133 Gloria furthermore justified Sergio’s reliance on Marcelo’s expertise by attributing to him some form of training—notwithstanding knowing him personally from his earlier time in the market and despite Marcelo’s own forthrightness about his education.Footnote 134 Meanwhile, the ‘average prescriptions’ Sergio had encountered and Marcelo’s advice—had created something like a standard antibiotic treatment for customers of the medicine-and-potato stall, closely echoing the process Rodrigues described: that a “standardisation of prescriptions” became “[…] a source of knowledge in self-medication practices” among patients.Footnote 135 In Sergio’s case, standardized prescriptions had become a source of knowledge for his IMS prescribing practices.

However, Sergio did not simply reproduce prescriptions. He adjusted them to fit previously encountered treatments and his notions of safety, another practice consistent with Rodrigues’ findings of patient-led prescription modification.Footnote 136 Yet another important reason behind Sergio’s “tinkering” with prescriptions was promoting access to medical healthcare in La Merced, even if indirectly.Footnote 137

According to Mexican pharmacy standards, prescriptions are supposed to be individual and personalized, and the rational drug use framework mandates that they must be followed to the doctor’s letter. Footnote 138 In contrast, in La Merced, Sergio “localized” antibiotic prescriptions in two ways.Footnote 139 Firstly, by measuring them against others he had encountered and coming to an almost mathematically average treatment—not seven, but three to five ceftriaxones.Footnote 140 Secondly, by reusing that average to recommend treatments to other patients with similar symptoms (e.g., green phlegm and/or throat-and-body pain).Footnote 141 Thus, Sergio ‘averaged’ antibiotic prescriptions and then collectivized them—practically making his ‘patients,’ with Gloria’s help, share medical consultations.Footnote 142

These practices and locals’ self-prescription placed ceftriaxone and amoxicillin among Sergio’s best-sellers (see Figure 4).Footnote 143 During fieldwork, RRG only once saw a customer with a prescription in Sergio’s stall. It was not for antibiotics. Nonetheless, Sergio continuously delivered ceftriaxone ampules, and pairs of Terramicina pills (oxytetracycline) across the market.Footnote 144 Some were customary deliveries, but others were Sergio’s “practical tinkering” to comply with a version of Marcelo’s version of antibiotic control.Footnote 145

Figure 4. The antibiotics section of the medicine-and-potato stall. The second and third levels from the top down are mostly filled with ceftriaxone ampules. Digital photo by RRG, La Merced market in Mexico City, April 12, 2024.

5.2. Delivering antibiotic treatment adherence

To mitigate the risk of “bacterial resistance,” the AMR-related term usually printed on antibiotic packaging warnings in Mexico, Sergio often took the precaution of making his customers finish their treatments.Footnote 146 He picked up this policy from Marcelo’s time in the market.

I’ve known for a long time that antibiotic treatments must be completed. … I’ve had it in mind, that they’re finished according to the prescription or my cousin’s suggestion, who sold them here [in the market]. … I’ve seen it myself. I’ve felt ill regarding bacteria and by the second or third doses I generally felt better. … But … I know that the treatment must be completed because if you don’t then it can bounce back or generate … bacterial resistance. So then, I have always emphasized to my patients who come get antibiotics that “treatment is for seven days or five days.” Injections, we work with a minimum of three doses … four or five would be ideal. … So we kill the bacteria the most we can.Footnote 147

Enacting Marcelo’s version of antibiotic control, however, was more challenging in La Merced than in Marcelo’s pharmacies. For Marcelo, his “contested” version consisted of warning his customers about the risks of not finishing their treatments.Footnote 148 For Sergio, enacting antibiotic control meant delivering doses of antibiotics across the market. Sergio tracked people down so they did not forget their antibiotic doses—either prescribed by a doctor or in the potato-and-medicine stall.Footnote 149 An important reason behind this practice was that customers in La Merced often did not buy what Sergio considered ‘complete’ treatments—for example, with ceftriaxone injections:

Normally they come and they just buy one. … When I know they’re [supposed to be] from three to five [doses]. I tell them to take the rest. They say they don’t have money. … If I know them, I tell them to take them, and they can pay me the next day. The goal is that they get the complete treatment. Because I’m left feeling remorse or the responsibility of saying, “these guys maybe … forget”, but I can’t disregard the situation as easily as they can. … If I don’t know them, I ask them where they sell [in the market] and I go see them. … The next day, I know they need their treatment and I’m worried and I sometimes look for them in their business. … I sometimes think I don’t take as good care of myself as I do them. But maybe, because of ignorance, they feel better from one or two antibiotic injections, and they might think the rest is because I want to sell. … But I’ve explained to them “It’s fine by me if you don’t take it, it’s not to sell you another antibiotic, but for yourself, so we don’t create a resistant bacterium”. Most of them understand.Footnote 150

Sergio cared very deeply about not letting his customers purchase or consume single doses of ceftriaxone, yet often had to accommodate their financial constraints. Specifically, the money his customers carried in their pockets when visiting his stall.Footnote 151 Many merchants in La Merced start the day off bringing to the market just enough money to give customers their change. Muggings are common in the area, especially for merchants, who are known to carry cash. Over the course of the day, they earn what they need to eat and pay their suppliers. Perhaps the most important reason behind single-dose purchasing is that many merchants scrape by with what they make every day, with very small profit margins.Footnote 152

This is why RRG often saw Sergio track people down to give them their doses, customers who were not always interested in continuing the treatment.

When I got to the market Gloria asked me to tell Sergio she had injected his customer, a woman who sells chicken soup. Around 4 pm, a little before the workday was over, Sergio said he had to go deliver medicine. I stayed in the “pharmacy” and when he came back, a few minutes later, he put a little box of ceftriaxone on the potato table. Since I was helping him set up the medicines on the shelves, I asked if the ceftriaxone box should be placed there too. He said it didn’t. He then told me the chicken soup seller had gotten angry because the first ceftriaxone dose had not had any effect. She had rejected the second dose, now just sitting beside the potatoes. The patient said she would best go to the doctor. Sergio said he did not like getting involved with patients after they had that sort of attitudes. He seemed distraught.Footnote 153

Sergio tracked his ‘patients’ down, let them borrow the medicines and pay later, and like that day, worried when he deemed the local ‘average’ antibiotic treatment was interrupted.Footnote 154 Thus, Sergio’s “practical tinkering” adjusted his practice, albeit less to official antibiotic control standards than to Marcelo’s “contested” version of antibiotic control.Footnote 155 A version in which it is “actually super good” to “indiscriminately” dispense antibiotics, so long as the seller takes measures to make customers complete their treatments.Footnote 156 Marcelo warned customers about the potential risks involved, while Sergio let them borrow antibiotics and chased them through the market with their subsequent doses.

Sergio recognized the “motivational ambivalence” of his practices, which could be interpreted as antibiotic pushing. Footnote 157 However, his report that acknowledging this ambivalence to his customers legitimized his antibiotic control practices suggests a degree of reflexivity on both sides of the transaction. This level of awareness would likely serve as a check on suspected profiteering. Indeed, it is reasonable to suppose that taking advantage of Sergio’s clientele—largely composed of experienced, multigenerational merchants—would not be easy, even when dealing in antibiotics.

A local doctor reflecting on Sergio’s prescription modifications and customer “chasing,” would later suggest that, at least in theory, he might have been preventing AMR.Footnote 158 This “functional ambivalence,” with optimization on one side and misuse on the other, hinged (at least) on Sergio and his customers completing treatments that matched the correct diagnosis, bug–drug combination, and dosage—a challenging proposition.Footnote 159 Evaluating Sergio’s practices becomes even more complex in light of ongoing debates surrounding the link between antibiotic treatment interruption and the development of resistance.Footnote 160 However, in the absence of formal oversight, Sergio’s antibiotic control reflected the ambivalent and “informal regulation” necessitated by La Merced’s healthcare itineraries—constrained by time, money and access.Footnote 161

6. Streetsmarts and care within ambivalence

Throughout this paper, we traced how two IMSs contested, adjusted, and reassembled antibiotic control standards in marginalized urban pharmaceutical outlets. Marcelo challenged antibiotic accounting standards as corruptly implemented; the prescription requirement as imposing unaffordable medical obligations on impoverished consumers; and the medical authority inscribed in prescriptions as excluding his clientele from access to effective antibiotics. In La Merced, Sergio and Gloria implicitly contested prescriptions themselves, which individualized and restricted an expensive resource that, in their view, can be shared: medical care. From the perspective of the IMSs we shadowed, these rationales legitimized their informal practices. They also manifested the latent normative, functional, and motivational ambivalence of their work, the latter often addressed through phrases echoing the sentiment that it’s not about the money. Yet, without exception, these rationales also aligned neatly with their economic interests. However, IMSs did not simply bypass standards and justify themselves. Marcelo emphasized communicating to customers that they had to finish their treatments, while Sergio delivered antibiotic doses to make sure they did—adapting antibiotic control to their businesses and communities.

These versions of antibiotic control have intertwined theoretical and policy implications. They show that informality can be studied as a localized, pragmatically reassembled version of formality, and, consequently, that such tinkering contains adjustments that may help better communicate and address AMR concerns at the street-level. Examples include telling customers that bacteria “vaccinate themselves” with antibiotics or creating guidelines to orient medicine sellers serving populations who can afford only single doses at a time. At the same time, IMSs’ tinkering responds to systemic failure—it does not resolve it.

The rationales and practices we presented highlight that antibiotic regulations can codify scientific knowledge into explanations, stakes, and responses to AMR, while embedding assumptions about the roles each member of the “… antibiotic care network[]” is willing and able to play.Footnote 162 However, unlike the science they partially draw on, these standards are seldom treated as open to ongoing debate. In Mexico, when they are modified, it is usually unilaterally, by a committee of experts. Yet, the distance between regulatory texts and street-level reality suggests that these experts lack (or sideline) streetsmarts: the knowledge developed in situations of marginality, where risk, regulation, corruption, poverty, and lay expertise converge.

While IMS tinkering produces situated forms of antibiotic control, it cannot reliably mitigate the risks created by weak official regulation and structural barriers to quality healthcare. In the case of AMR, particularly when treatment begins without diagnosis or prescription, tinkering cannot compensate for widespread inappropriate antibiotic dispensing, nor can any rationale justify the risks it entails. Informal adjustments may ease some consequences of inequality, but they cannot substitute access to doctors, prescriptions, functional health systems, and reliable oversight. As Rodrigues argues: “… individuals’ rationales should not be seen as part of the problem, but should rather be incorporated into the solution.”Footnote 163 The same goes for their tinkering. Designing effective and just antibiotic regulations requires incorporating street-level expertise and ingenuity—without treating them as a panacea for structural exclusion.

Our ethnographic immersion restricted us to shadowing a small number of IMSs, limiting generalizability. However, the ubiquity of the types of establishments our interlocutors worked in suggests that their concerns and practices likely echo those of other IMSs in Mexico City, especially in marginalized neighborhoods. Our findings also carry broader implications for research on IMSs globally.

We stress that scholarship on IMSs must recognize their capacity to reflect on their dual role and sustain care within ambivalence. This is not a call to romanticize IMSs, but to shift attention from their double incentives—however analytically intriguing—to the practical value and potential of their work in context. Treating their justifications for rule-bending as fully formed rationales is essential to understanding the systemic failures that give them rhetorical and ethical force. Corruption and inadequate healthcare make a good case for breaking the rules, and the profitability of IMS care should not discount their accounts of the real problems their informal practices address. Breaking the rules may stem from economic self-interest but remaking them from the bottom up takes real care.

Acknowledgements

We are deeply grateful to the informants whose generosity made this research possible. We thank our anonymous reviewers for their thoughtful comments, and Larissa Arreola for helping in interpreting Mexico’s healthcare landscape. Ethnographic fieldwork and writing were supported by British Academy Global Convening Programme Funding (GCPS2\100009), with additional support from Wellcome Trust grant 212584/B/18/Z.

Author contribution

Conceptualization: R.R.-G.; R.G.

Funding Statement

The research and writing of this publication were partially supported with funding from the British Academy Global Convening Programme (GCPS2\100009). The funder had no influence on the design or the outcomes of this study, which are the sole responsibility of the authors. Open access funding provided by University of Amsterdam.

Conflicts of Interest

The authors declare no competing interests.

Footnotes

1 This statement draws on research of informal pharmaceutical or medical product markets. On informal sector sellers adjusting to customers’ financial constraints see Dagrou and Chimhutu Reference Dagrou and Victor2022, 7–8; on the drivers of informal medical product markets in low- and middle-income countries, including customer trust and public health system dysfunction, see Health Action International 2023, 69–71 (unpublished); on medicine sellers offering first response care see Hughes et al. Reference Hughes, Chandler, Mangham-Jefferies and Mbacham2013, 641.

2 See Oga-Omenka, Okafor, and Sulis Reference Oga-Omenka, Okafor and Sulis2023 for a source linking medicine vendors in poorly regulated contexts with inappropriate antibiotic dispensing and AMR; see Kumah Reference Kumah2022, 2 for a source linking drug vendors as informal healthcare providers with nonprescription trade of prescription-only medications; see Afari-Asiedu et al. Reference Afari-Asiedu, Abdulai, Tostmann, Boamah-Kaali, Asante, Heiman and Hulscher2022, 259 for a source linking over-the-counter medicine sellers with the nonprescription dispensing of antibiotics against regulations and AMR; see Tandan et al. Reference Tandan, Thapa, Bhandari, Gandra, Timalsina, Bohora, Thapaliya, Bhusal, Gore, Sheokand, Shukla, Joshi, Mudgal, Pai and Sulis2024 for a source associating the unregulated sale and dispensing of antibiotics by informal healthcare providers with AMR. See Sudhinaraset et al. Reference Sudhinaraset, Ingram, Lofthouse and Montagu2013, 1–2 for common characteristics of healthcare providers deemed “informal,” including lack of official registration, strict oversight, and requisite qualifications, which we use to define “informal medicine sellers” (IMSs) in this paper.

4 See Hayden Reference Hayden2023. Cori Hayden’s work has focused on the proliferation of generic medicines in Mexico and touches on the multiplication of formal and informal pharmacies in Mexico City. To our knowledge, it is the closest academic analysis of popular pharmaceutical commerce in Mexico.

5 See Gómez-Dantés et al. Reference Gómez-Dantés, Dreser, Wirtz and Reich2022 on how reforms to the public pharmaceutical procurement system contributed to nationwide medicine shortages; see Reich Reference Reich2020 for a detailed account of the termination and attempted replacement of Seguro Popular with INSABI, a then-new subsystem aimed at the uninsured population; see Serván-Mori et al. Reference Serván-Mori, Gómez-Dantés, Contreras, Flamand, Cerecero-García, Arreola-Ornelas and Knaul2023, 8–9 on coverage interruptions associated with this attempted replacement; see Noticias Reference Azteca2025 for a report linking medicine shortages with demand for medicines in street markets; see Bloomberg Reference Bloomberg2022 for a representative of the Mexican pharmaceutical industry linking coverage drops and medicine shortages with the rise of demand for medicines in the “black market”; see Rodríguez Reference Rodríguez2023 for a report linking the “black market” with shortages and the COVID-19 pandemic; see Vega Reference Vega2022 for a report linking health system reforms, the COVID-19 pandemic, increases in health-related spending and demand for medicines in the “black market.”

6 See NMás 2020 and Azteca Noticias Reference Azteca2024 on street market vendors in Mexico City selling antibiotics without prescriptions and in illegal outlets; see Svarch et al. 2024, Reference Tandan, Thapa, Bhandari, Gandra, Timalsina, Bohora, Thapaliya, Bhusal, Gore, Sheokand, Shukla, Joshi, Mudgal, Pai and Sulis83Reference Tillmann-Healy84 for an overview of some of the AMR-related regulations that such practices contravene.

7 See Amabile-Cuevas Reference Amabile-Cuevas2021, 443 regarding a previous trend of decreasing antibiotic consumption in Mexico and its potential link to economic conditions; see Bloomberg Reference Bloomberg2022, on the possible relation between public medicine shortages and demand for “black market” medicines; see Serván-Mori et al. Reference Serván-Mori, Gómez-Dantés, Contreras, Flamand, Cerecero-García, Arreola-Ornelas and Knaul2023, 8 on an increased prevalence of excessive health expenditures in Mexico, following the termination of Seguro Popular.

8 Institute for Health Metrics and Evaluation n.d, 1.

10 See Svarch et al. Reference Svarch, Rosales, Contreras, Lugo, Vázquez and Sandoval2024, 83–84 for a brief history and overview of “Control of Antibiotics” regulations; see FEUM 2018, 219–24 to consult the framework directly. See FEUM 2018, XVI for a mention of committees of experts within the Mexican Pharmacopoeia’s organization, the organization in charge of making, editing, and publishing pharmaceutical outlet regulations in Mexico. An unspecified “committee of experts” is credited by Svarch et al. Reference Svarch, Rosales, Contreras, Lugo, Vázquez and Sandoval2024, 84 (who are the former head of COFEPRIS and his helpers) with contributing to this regulatory framework.

11 Ibid.

12 See Hayden Reference Hayden2023, 144–177; additionally, see 169 for her research participant’s remark.

13 See Suy et al. Reference Suy, Rego, Bory, Chhorn, Phou, Prien, Heng, Wu, Legido-Quigley, Hanefeld, Saphonn and Khan2019 on the invisibility of medicine sellers, which they broadly define as the quality of not having a signposted and designated space to conduct their business, making it difficult for authorities to conduct inspections. Drawing on Scott Reference Scott1998 and his perspective of state visibility, we broaden the term to signify those for which official inspections and audits are complicated for any reason, such as not having a designated space, avoiding registration, or simply popping up without obtaining any licensing. See Timmermans and Epstein Reference Timmermans and Epstein2010, 79 on unimplemented standards being “paper tigers.”

14 See Azteca Noticias Reference Azteca2025 for a report on medicine street markets; see FEUM 2018, 213–18 for the many prohibitions the sellers and buyers of medicines in street markets violate. Presumably, effective oversight would not allow these activities to go on. Additionally, adding street markets to informal drug shops likely diversifies the regulatory tasks needed to control the informal market and highlights the various forms it can take.

16 See Afari-Asiedu et al. Reference Afari-Asiedu, Abdulai, Tostmann, Boamah-Kaali, Asante, Heiman and Hulscher2022, 272–73 on educational interventions to improve antibiotic dispensing; cf. Hutchinson et al. Reference Hutchinson, Mundua, Ochero, Mbonye and Clarke2022, 7—this research group raised the possibility that the substitution of untrained medicine sellers by trained practitioners in Uganda could lead to a loss of localized forms of care and credit.

17 See Gryseels et al. Reference Gryseels, Kuijpers, Jacobs and Grietens2019 on the substandard becoming the standard; see Kamenshchikova et al. Reference Kamenshchikova, Fedotova, Fedorova, Fedosenko, Petra, Christian and Horstman2021 on informal antibiotic infrastructures emerging to make up for health system shortcomings; see Hutchinson et al. Reference Hutchinson, Hansen, Sanyu, Amonya, Mundua, Balabanova, Clarke and Kitutu2023 on whether it is financially possible, given their business operations, for certain drug shops to comply with regulations.

18 See Nichter and Vuckovic Reference Nichter and Vuckovic1994, 1509 and Rodrigues Reference Rodrigues2020 on “rationales”; see Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021 on “the social life of standards”.

19 On “ambivalence”, see Ledeneva Reference Ledeneva, Ledeneva, Bailey, Barron, Curro and Teague2018, 7.

20 On “reassembled” standards, see Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 19.

23 See Lomnitz Reference Lomnitz1988.

25 Koster Reference Koster2019; Scott Reference Scott1998, 310; for an example of entwinement in pharmaceutical distribution and markets see van der Geest Reference van der Geest1985.

26 See Kingori and Gerrets Reference Kingori and Gerrets2019 on continuums instead of dichotomies and grey areas in Global Health; see Koster and Smart Reference Koster and Smart2019 on varying, contextually shaped forms of informality entwined with formality.

28 Idem, 7–9.

29 Idem, 10–15. See 10–11 on “normative ambivalence”; see 11–12 on “functional ambivalence”; see 13–15 on “motivational ambivalence.”

30 See Cross and MacGregor Reference Cross and MacGregor2010, 1596–98 for a review of studies about informal markets for medicine and their emphasizing of sellers’ economic self-interest or socially regulated care practices. We agree with Cross and MacGregor Reference Cross and MacGregor2010, 1596 that these “paradoxical understandings” flatten the “sociological complexity” of IMS dynamics.

33 See Cohen et al. Reference Cohen, McCubbin, Collin and Pérodeau2001, 445 on “… individual and local logics…” of pharmaceutical use; see Nichter and Vuckovic Reference Nichter and Vuckovic1994, 1509, 1514 on “rationales” and a critique of perspectives centering the rational use framework.

34 Willis, Laurie, and Chandler Reference Willis, Laurie and Chandler2023, 384.

35 Rodrigues Reference Rodrigues2020.

38 See Broom et al. Reference Broom, Broom, Kirby, Gibson and Davis2017, 58–62 for a critique of center-periphery antibiotic stewardship guidelines; see Kamenshchikova et al. Reference Kamenshchikova, Fedotova, Fedorova, Fedosenko, Petra, Christian and Horstman2021, 360–62 for critique of the top-down prescription requirement.

39 Rodrigues Reference Rodrigues2020, 5–8.

40 For an example of such discrediting see Cross and MacGregor Reference Cross and MacGregor2010, 1598.

42 Álvarez Reference Álvarez2019.

43 Ibid.

44 Boholm Reference Boholm2003, 172–73.

45 See Rangel-Gutiérrez, Reference Rangel-Gutiérrezforthcoming.

46 See Busch Reference Busch2011, 13 for a definition of standards as rules for people and things; see Lampland and Star Reference Lampland and Star2009, 9–10, including the footnotes, on the relationship between standards and formal representation.

48 See Busch Reference Busch2011, 217–19 for a discussion on the relationship between standards and science; see Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 19 on standards presenting as “the” universal or correct way of doing something.

49 Timmermans and Epstein Reference Timmermans and Epstein2010, 79.

50 Suzuki Reference Suzuki2021, 732–35. See page 733 on “practical tinkering.”

52 Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 13–15. See page 13 on “subverted” standards and page 15 on “contested” standards.

53 See Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 19 on “reassembled” standards; see Busch Reference Busch2011, 74–75 for an explanation of standards as “scripts” that shape enactments; see Mol Reference Mol2002 on “enactment.”

54 See Suzuki Reference Suzuki2021, 733 on “practical tinkering”; Busch Reference Busch2011, 74–75 on standards as scripts; and Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 16–17 on legal reassemblings of standards.

55 See Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 19 on “localized” and “reassembled” standards.

56 See McDermott Reference McDermott2025, 941 on the population of the Mexico City Metropolitan Area anno 2020; see Aguilar et al. Reference Aguilar, Flores and Lara2022, 4 for corroboration about the date of this population number; see Aguilar and Hernandez-Lozano Reference Aguilar and Hernandez-Lozano2024, 4–5 on the territorial composition of Mexico City, its metropolitan area and Mexico’s central region.

57 See Doubova et al. Reference Doubova, García-Saiso, Pérez-Cuevas, Sarabia-González, Pacheco-Estrello, Infante-Castañeda, Santamaría, del Pilar Torres-Arreola and Leslie2018 on Mexico’s “pluralistic” health system including decentralized public subsystems and private providers; see Gómez-Dantés et al. Reference Gómez-Dantés, Flamand, Cerecero-García, Morales-Vazquez and Serván-Mori2023 on the “fragmentation” and systemic exclusions of the Mexican health system; see López-Arellano and Delgado-Campos Reference López-Arellano and Delgado-Campos2024 for an overview of recent changes to the legal framework and infrastructure of Mexico City’s public health system, including contributive social security and “free” subsystems, and the latter’s hospitals, clinics and health centers; see INEGI 2025b, 2–5 on private hospitals and practices (only establishments with hospital beds were counted) in Mexico City.

58 See López-Arellano and Delgado-Campos Reference López-Arellano and Delgado-Campos2024 on public healthcare infrastructure in Mexico City; INEGI 2025a, 2025b, 2–5 on private hospitals and practices in Mexico City; see Osorio Carranza Reference Osorio, María, Gamlin, Gibbon, Sesia and Berrio2020 and Hayden Reference Hayden2023 on pharmacies with annexed consultation rooms in Mexico City; separately, see also Hayden Reference Hayden2023, 168–77 on independent pharmacies. For the density of registered small-scale pharmaceutical retail, see INEGI 2025a for the DENUE database for the category Comercio al por menor de productos farmacéuticos y naturistas—pharmaceutical and naturist products retail (our search looked at establishments with up to five employees), which returned 8,473 listings in Mexico City as of November 23, 2025. Finally, note that INEGI and CANIFARMA 2024, a report of a special, first-time survey of the pharmaceutical industry shows that only businesses with 11 or more employees were counted, illustrating how micro-retail becomes obscured as a part of the pharmaceutical industry.

59 See Gómez-Dantés et al. Reference Gómez-Dantés, Flamand, Cerecero-García, Morales-Vazquez and Serván-Mori2023, 2–4 on the development of the national health system and “contributive social security” exclusions in relation to López-Arellano and Delgado-Campos Reference López-Arellano and Delgado-Campos2024, 690 on Mexico City’s population without employment-based social security.

60 See Gómez-Dantés et al. Reference Gómez-Dantés, Flamand, Cerecero-García, Morales-Vazquez and Serván-Mori2023, 4 on the historical dependence of those without contributive social security on “public charity”; additionally, see 2–3 on the private sector providing care to those with the “capacity-to-pay” and an overview of the social protection schemes that have attempted to address this systemic exclusion, starting with 2003’s Seguro Popular.

61 Studies have suggested that negative appraisals and experiences of public healthcare have contributed to insured patients seeking private services in Mexico; see Doubova et al. Reference Doubova, Leslie, Pérez-Cuevas, Kruk and Arsenault2024, 5–9; Osorio Carranza Reference Osorio, María, Gamlin, Gibbon, Sesia and Berrio2020, 212–5; Pérez-Cuevas et al. Reference Pérez-Cuevas, Doubova, Wirtz, Servan-Mori, Dreser and Hernández-Ávila2014, 6; .

62 See Osorio Carranza Reference Osorio, María, Gamlin, Gibbon, Sesia and Berrio2020 on the role of low-cost pharmacies with consultation rooms; see Hayden Reference Hayden2023 for a source focusing on pharmacies carrying generics, also with annexed consultation rooms.

63 Hayden Reference Hayden2023, 168–77; see Ibid, 169 on “mom-and-pop” generics pharmacies.

64 See Pérez-Cuevas et al. Reference Pérez-Cuevas, Doubova, Wirtz, Servan-Mori, Dreser and Hernández-Ávila2014, 6 on how “doctors” offices adjacent to private pharmacies’ (DAPPs) “promote inequity and out-of-pocket expenditures”; see Osorio Carranza Reference Osorio, María, Gamlin, Gibbon, Sesia and Berrio2020, 216–217 on the government’s delegation of its responsibility to provide healthcare to the private sector. While these sources do not focus specifically on informal drug shops with consultation rooms, we take these critiques to extend to them as well.

65 See Gómez-Dantés et al. Reference Gómez-Dantés, Flamand, Cerecero-García, Morales-Vazquez and Serván-Mori2023, 3 on “contributive social security”; see idem. on “capacity-to-pay” being the key requisite to access private healthcare in Mexico and the increased vulnerability of the “population lacking contributive social security” to recent policy reforms, including the dismantling of Seguro Popular and its successor, INSABI.

66 See México Evalúa Reference Evalúa2025, 28. It is important to note that the massive transformations of the national health system (from Seguro Popular to INSABI and then to IMSS-Bienestar) have produced significant uncertainty in measuring “lack of access to health services.” For example, Gómez-Dantés et al. Reference Gómez-Dantés, Serván-Mori, Cerecero, Flamand and Mohar2024, 96 note that one estimate placed the population “lacking access” at “50 million in 2022”, but this figure was likely inflated because survey respondents were asked whether they “had public health insurance”—a question many answered without knowing that former beneficiaries of Seguro Popular had been transferred to INSABI. As Gómez-Dantés et al. Reference Gómez-Dantés, Serván-Mori, Cerecero, Flamand and Mohar2024, 96 explain, IMSS-Bienestar’s formal affiliation process will likely make coverage more visible to future respondents. Thus, we cite Mexico Evalúa’s calculation while acknowledging the transitional moment it reflects. Still, we would emphasize that a population unaware of its coverage is, in practice, very similar to one that lacks it. People might discover they are insured in an emergency, but even that is uncertain. Put differently: if someone “has” health insurance in the middle of a forest but no one has told them, do they really have it at all?

68 Figures from México Evalúa Reference Evalúa2025, 18–19, 21, based on analysis of ENIGH (National Household Income and Expenditure Survey) 2018–2024. Out-of-pocket health expenditures rose 41.4% nationwide (approximately 470 MXN more per household per quarter), and spending on medicines doubled (116% increase, from 222 MXN per household per quarter in 2018 to 480 MXN in 2024).

69 See Gómez-Dantés et al. Reference Gómez-Dantés, Dreser, Wirtz and Reich2022; see also Gómez Reference Gómez2024 on the “Megapharmacy,” an attempt by the federal government to solve medicine shortages in the public sector.

70 See Footnote footnote 5 in relation to Bloomberg Reference Bloomberg2022; Azteca Noticias Reference Azteca2025; Rodríguez Reference Rodríguez2023; Vega Reference Vega2022.

71 See COFEPRIS 2024 for a report on stolen medicines, advising consumers, in page 3, not to purchase medicines in street markets and public markets. “Public markets” in Mexico usually refers to established food and grocery markets where many types of vendors work in the same area, often in the same building.

72 See Azteca Noticias Reference Azteca2025 and NMás 2023 for journalistic reports showing street outlets without consultation rooms and stating that street markets carry falsified medicines.

73 See Azteca Noticias Reference Azteca2025 for a report documenting the sale of controlled pharmaceuticals without a medical prescription in a street market; see NMás 2020 and Noticias Reference Azteca2024 for reports showing the nonprescription sale of antibiotics in street markets.

74 See Marcus Reference Marcus1995, 106–8.

75 See Kusenbach Reference Kusenbach2003 on the “go-along”; see Tillmann-Healy Reference Tillmann-Healy2003 on “Friendship as Method”, which includes hanging out for extended periods of time.

76 See FEUM 2018 for the Supplement; see Secretaría de Salud 1984 for Mexico’s General Law of Health.

77 Fereday and Muir-Cochrane Reference Fereday and Muir-Cochrane2006, 81.

78 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

79 Ibid.

80 Interview with Sergio, potato seller-and-IMS, central Mexico City, March 6, 2024.

81 Ibid.

82 Ibid.

83 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

84 Fieldnotes, April 16, 2024; interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

85 Ibid.

86 Ibid.

87 We are counting Marcelo’s main shop as one, even though it has two storefronts. Fieldnotes, April 16, 2024; interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

88 Ibid.

89 Fieldnotes, April 16, 2024.

90 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

91 Ibid.

92 FEUM 2018, 227.

93 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

94 Smith Reference Smith2007, 17–18.

95 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

97 On the proliferation of accounting techniques as surveillance and monitoring technologies see Shore and Wright Reference Shore and Wright2015, 421; on “subverted” standards, see Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 13.

98 See Ledeneva Reference Ledeneva, Ledeneva, Bailey, Barron, Curro and Teague2018, 10–13 on “motivational ambivalence” and “normative ambivalence.”

99 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

100 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

101 Amabile-Cuevas Reference Amabile-Cuevas2021, 443.

102 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

103 See Chandler Reference Chandler2019, 7.

104 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

105 See Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 15 on “contested” standards.

106 See FEUM 2018, 3 on pharmaceutical deontology standards.

107 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

108 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

109 See Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 15 on “contested” standards.

111 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

112 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

113 Recorded phone call between Marcelo and Sergio, IMS cousins, central Mexico City, April 17, 2024.

114 Rodrigues Reference Rodrigues2020, 5–6.

115 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

116 See Ledeneva Reference Ledeneva, Ledeneva, Bailey, Barron, Curro and Teague2018, 12 on “need” versus “greed” in informal practices.

117 See Suzuki Reference Suzuki2021, 733 on “tinkering.”

118 See Busch Reference Busch2011, 2 on standards and language; see Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 19 on “localized” standards.

119 See Will Reference Will2020, 17 on the “use of ignorance” and misunderstandings surrounding AMR, including resistance building up in the body.

120 See Suzuki Reference Suzuki2021, 733 on “tinkering.”

121 Fieldnotes, March 20, 2024.

122 Fieldnotes, February 26, 2024; interview with Sergio, potato seller-and-IMS, central Mexico City, March 6, 2024.

123 Interview with Sergio, potato seller-and-IMS, central Mexico City, April 17, 2024.

124 Fieldnotes, February–April, 2024.

125 Fieldnotes, February–April 2024.

126 Interview with Gloria, market vendor and Sergio’s unpaid helper, central Mexico City, February 22, 2024.

127 Ibid.

128 Ibid.

129 See Suzuki Reference Suzuki2021, 733 on “tinkering.”

130 Fieldnotes, February–April 2024.

131 Fieldnotes, February 23, 2024.

132 Interview with Gloria, market vendor and Sergio’s unpaid helper, central Mexico City, February 22, 2024.

133 Ibid.

134 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

135 Rodrigues Reference Rodrigues2020, 5.

136 See Rodrigues Reference Rodrigues2020, 7 on patient-led prescription modifications.

137 See Suzuki Reference Suzuki2021, 733 on “tinkering.”

138 See FEUM 2018, 109 on elements of a prescription, including patient names to avoid mix ups; see Cohen et al. Reference Cohen, McCubbin, Collin and Pérodeau2001, 444 on the rational drug use framework.

139 See Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 19 on “localized” standards.

140 Interview with Gloria, market vendor and Sergio’s unpaid helper, central Mexico City, February 22, 2024; Interview with Sergio, potato seller-and-IMS, central Mexico City, March 25, 2024.

141 Interview with Sergio, potato seller-and-IMS, central Mexico City, April 11, 2024; interview with Sergio, potato seller-and-IMS, central Mexico City, April 11, 2024.

142 Interview with Gloria, market vendor and Sergio’s unpaid helper, central Mexico City, February 22, 2024; Fieldnotes, February–April 2024.

143 Interview with Sergio, potato seller-and-IMS, central Mexico City, March 6, 2024.

144 Fieldnotes, April 4, 2024.

145 See Suzuki Reference Suzuki2021, 733 on “practical tinkering.”

146 Interview with Sergio, potato seller-and-IMS, central Mexico City, March 25, 2024.

147 Ibid.

148 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024. See Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 15 on “contested” standards.

149 Fieldnotes, April 4, 2024.

150 Interview with Sergio, potato seller-and-IMS, central Mexico City, March 25, 2024.

151 Fieldnotes, March 19, 2024.

152 Fieldnotes, February 22, 2024.

153 Fieldnotes, March 6, 2024.

154 Interview with Sergio, potato seller-and-IMS, central Mexico City, March 25, 2024.

155 See Suzuki Reference Suzuki2021, 733 on “practical tinkering”; see Graham et al. Reference Graham, Holmes, McDonald, Darnell, Graham, Holmes, McDonald and Darnell2021, 15 on “contested” standards.

156 Interview with Marcelo, unlicensed pharmacy owner, Greater Mexico City, April 16, 2024.

157 See Ledeneva Reference Ledeneva, Ledeneva, Bailey, Barron, Curro and Teague2018, 13 on “motivational ambivalence.”

158 Informal telephonic conversation with local doctor “A,” fieldnotes, May 17, 2024. No other medical professionals were consulted.

159 See Ledeneva, Reference Ledeneva, Ledeneva, Bailey, Barron, Curro and Teague2018, 12 on “functional ambivalence”; informal telephonic conversation with local doctor “A,” fieldnotes, May 17, 2024.

160 See Amabile-Cuevas Reference Amabile-Cuevas2022, 395–396.

161 See Flom, Reference Flom2022, 24 on a theory defining informal regulation as the alignment of market activity with standards through unwritten mechanisms.

162 See Kamenshchikova et al. Reference Kamenshchikova, Fedotova, Fedorova, Fedosenko, Petra, Christian and Horstman2021, 365 on “antibiotic care networks”; see Busch Reference Busch2011, 217–19 on the relationship between standards and science; see Timmermans and Epstein Reference Timmermans and Epstein2010, 79 on standards imposing roles on people; see Higgins and Larner Reference Higgins, Larner, Higgins and Larner2010, 4 on standards defining problems, stakes, ways of evaluating and solving them.

163 Rodrigues Reference Rodrigues2020, 10.

References

Afari-Asiedu, Samuel, Abdulai, Martha Ali, Tostmann, Alma, Boamah-Kaali, Ellen, Asante, Kwaku Poku, Heiman, F. L. Wertheim, and Hulscher, Marlies. 2022. “Interventions to Improve Dispensing of Antibiotics at the Community Level in Low and Middle Income Countries: A Systematic Review.” Journal of Global Antimicrobial Resistance 29: 259–74. https://doi.org/10.1016/j.jgar.2022.03.009.CrossRefGoogle Scholar
Afari-Asiedu, Samuel, Hulscher, Marlies, Abdulai, Martha Ali, Boamah-Kaali, Ellen, Asante, Kwaku Poku, and Heiman, F. L. Wertheim. 2020. “Every Medicine Is Medicine; Exploring Inappropriate Antibiotic Use at the Community Level in Rural Ghana.” BMC Public Health 20 (1): 1103. https://doi.org/10.1186/s12889-020-09204-4.CrossRefGoogle Scholar
Aguilar, Adrian Guillermo, Flores, Miguel Angel, and Lara, Luis Fernando. 2022. “Peri-Urbanization and Land Use Fragmentation in Mexico City. Informality, Environmental Deterioration, and Ineffective Urban Policy.” Frontiers in Sustainable Cities 4: 790474. https://doi.org/10.3389/frsc.2022.790474.CrossRefGoogle Scholar
Aguilar, Adrian Guillermo, and Hernandez-Lozano, Josefina. 2024. “Mega-Urbanization, Territorial Fragmentation and Social Inequality in the Global South: The Case of Mexico City and its City-Region.” Applied Geography 163: 103183. https://doi.org/10.1016/j.apgeog.2023.103183.CrossRefGoogle Scholar
Álvarez, Xochitl. 2019. “Medicinas en tianguis ‘que ni el Seguro tiene.’” El Universal, June 18. https://www.eluniversal.com.mx/estados/medicinas-en-tianguis-que-ni-el-seguro-tiene/.Google Scholar
Amabile-Cuevas, Carlos F. 2021. “Antibiotic Usage and Resistance in Mexico: An Update after a Decade of Change.” The Journal of Infection in Developing Countries 15 (04): 442–49. https://doi.org/10.3855/jidc.13467.CrossRefGoogle ScholarPubMed
Amabile-Cuevas, Carlos F. 2022. “Myths and Misconceptions around Antibiotic Resistance: Time to Get Rid of Them.” Infection & Chemotherapy 54 (3): 393. https://doi.org/10.3947/ic.2022.0060.CrossRefGoogle ScholarPubMed
Azteca, Noticias. 2024. “¡Peligro En CDMX! Venden En Tianguis Antibióticos Y Pomadas Íntimas Sin Receta Médica.” Youtube Video 02: 44. https://www.youtube.com/watch?v=UB-0id6bV8Q.Google Scholar
Azteca, Noticias. 2025. “La Escasez de Medicamentos En Hospitales ha Contribuido a Que Crezca El Mercado Negro. Youtube Video 2: 13. https://www.youtube.com/watch?v=HbYWXxV36pU.Google Scholar
Belachew, Sewunet Admasu, Hall, Lisa, Erku, Daniel Asfaw, and Selvey, Linda A.. 2021. “No Prescription? No Problem: Drivers of Non-Prescribed Sale of Antibiotics among Community Drug Retail Outlets in Low and Middle Income Countries: A Systematic Review of Qualitative Studies.” BMC Public Health 21 (1): 1056. https://doi.org/10.1186/s12889-021-11163-3.CrossRefGoogle ScholarPubMed
Bloomberg, El Financiero. 2022. “Mercado “Negro” de Medicinas Aumenta En México.” Youtube Video 4: 18. https://www.youtube.com/watch?v=liPzUW5kXEY.Google Scholar
Boholm, Åsa. 2003. “The Cultural Nature of Risk: Can there be an Anthropology of Uncertainty?Ethnos 68 (2): 159–78. https://doi.org/10.1080/0014184032000097722.CrossRefGoogle Scholar
Broom, Alexander, Broom, Jennifer, Kirby, Emma, Gibson, Alexandra, and Davis, Mark. 2017. “Antibiotic Optimisation in ‘the Bush’: Local Know-how and Core-Periphery Relations.” Health & Place 48: 5662. https://doi.org/10.1016/j.healthplace.2017.09.003.CrossRefGoogle ScholarPubMed
Busch, Lawrence. 2011. Standards: Recipes for Reality. MIT Press.10.7551/mitpress/8962.001.0001CrossRefGoogle Scholar
Chandler, Clare I. R. 2019. “Current Accounts of Antimicrobial Resistance: Stabilisation, Individualisation and Antibiotics as Infrastructure.” Palgrave Communications 5 (1): 53. https://doi.org/10.1057/s41599-019-0263-4.CrossRefGoogle ScholarPubMed
Chandler, Clare I. R., Jones, Caroline, Boniface, Gloria, Juma, Kaseem, Reyburn, Hugh, and Whitty, Christopher Jm. 2008. “Guidelines and Mindlines: Why Do Clinical Staff over-Diagnose Malaria in Tanzania? A Qualitative Study.” Malaria Journal 7 (1): 53. https://doi.org/10.1186/1475-2875-7-53.CrossRefGoogle ScholarPubMed
COFEPRIS. 2024. “Alerta sanitaria de robo de medicamentos Vaporub y Vitapyrena Forte.” COFEPRIS, May 17. https://www.gob.mx/cms/uploads/attachment/file/916632/Alerta_sanitaria_de_robo_de_medicamentos_vaporub_y_vitapyrena_17052024.pdf.Google Scholar
Cohen, David, McCubbin, Michael, Collin, Johanne, and Pérodeau, Guilhème. 2001. “Medications as Social Phenomena.” Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine 5 (4): 441–69. https://doi.org/10.1177/136345930100500403.CrossRefGoogle Scholar
Cross, Jamie, and MacGregor, Hayley Nan. 2010. “Knowledge, Legitimacy and Economic Practice in Informal Markets for Medicine: A Critical Review of Research.” Social Science & Medicine 71 (9): 15931600. https://doi.org/10.1016/j.socscimed.2010.07.040.CrossRefGoogle ScholarPubMed
Dagrou, Armel, and Victor, Chimhutu. 2022. “I Buy Medicines From the Streets Because I Am Poor: A Qualitative Account on Why the Informal Market for Medicines Thrive in Ivory Coast.” INQUIRY: The Journal of Health Care Organization, Provision, and Financing 59: 004695802210865. https://doi.org/10.1177/00469580221086585.Google Scholar
De la Peña, Guillermo. 2000. “Corrupción e Informalidad.” In Vicios Públicos, Virtudes Privadas. La Corrupción En México, edited by Lomnitz-Adler, Claudio, 1st. edn., 113–28. CIESAS and M.A. Porrúa.Google Scholar
Doubova, Svetlana V., García-Saiso, Sebastián, Pérez-Cuevas, Ricardo, Sarabia-González, O., Pacheco-Estrello, P., Infante-Castañeda, C., Santamaría, C., del Pilar Torres-Arreola, L., and Leslie, H. H.. 2018. “Quality Governance in a Pluralistic Health System: Mexican Experience and Challenges.” The Lancet Global Health 6 (11): e1149–52. https://doi.org/10.1016/S2214-109X(18)30321-8.CrossRefGoogle Scholar
Doubova, Svetlana V., Leslie, Hannah H., Pérez-Cuevas, Ricardo, Kruk, Margaret E., and Arsenault, Catherine. 2024. “Users’ Perception of Quality as a Driver of Private Healthcare Use in Mexico: Insights from the People’s Voice Survey.” PLoS One 19 (6): e0306179. https://doi.org/10.1371/journal.pone.0306179.CrossRefGoogle ScholarPubMed
Fereday, Jennifer, and Muir-Cochrane, Eimear. 2006. “Demonstrating Rigor Using Thematic Analysis: A Hybrid Approach of Inductive and Deductive Coding and Theme Development.” International Journal of Qualitative Methods 5 (1): 8092. https://doi.org/10.1177/160940690600500107.CrossRefGoogle Scholar
FEUM. 2018. Suplemento Para Los Establecimientos Dedicados a La Venta y Suministro de Medicamentos y Demás Insumos Para La Salud, 6th edn. Secretaría de Salud-FEUM.Google Scholar
Flom, Hernán. 2022. The Informal Regulation of Criminal Markets in Latin America, 1st edn. Cambridge University Press. https://doi.org/10.1017/9781009170710.CrossRefGoogle Scholar
Gautham, Meenakshi, Spicer, Neil, Chatterjee, Soumyadip, and Goodman, Catherine. 2021. “What Are the Challenges for Antibiotic Stewardship at the Community Level? An Analysis of the Drivers of Antibiotic Provision by Informal Healthcare Providers in Rural India.” Social Science & Medicine 275: 113813. https://doi.org/10.1016/j.socscimed.2021.113813.CrossRefGoogle Scholar
Gómez, Enrique. 2024. “Megafarmacia, sin 99% de los medicamentos.” El Universal, January 30. https://www.eluniversal.com.mx/nacion/megafarmacia-sin-99-de-los-medicamentos/.Google Scholar
Gómez-Dantés, Octavio, Dreser, Anahi, Wirtz, Veronika J., and Reich, Michael R.. 2022. “Challenges of Guaranteeing Access to Medicines in Mexico: Lessons from Recent Changes in Pharmaceuticals Procurement.” Health Systems & Reform 8 (1): 2084221. https://doi.org/10.1080/23288604.2022.2084221.CrossRefGoogle ScholarPubMed
Gómez-Dantés, Octavio, Flamand, Laura, Cerecero-García, Diego, Morales-Vazquez, Mariana, and Serván-Mori, Edson. 2023. “Origin, Impacts, and Potential Solutions to the Fragmentation of the Mexican Health System: A Consultation with Key Actors.” Health Research Policy and Systems 21 (1): 80. https://doi.org/10.1186/s12961-023-01025-2.CrossRefGoogle Scholar
Gómez-Dantés, Octavio, Serván-Mori, Edson, Cerecero, Diego, Flamand, Laura, and Mohar, Alejandro. 2024. “Mexico’s Health System, 2023.” Salud Pública de México 67 (1): 91105. https://doi.org/10.21149/15802.CrossRefGoogle ScholarPubMed
Graham, Janice, Holmes, Christina, McDonald, Fiona, and Darnell, Regna. 2021. “Introduction.” In The Social Life of Standards: Ethnographic Methods for Local Engagement, edited by Graham, Janice, Holmes, Christina, McDonald, Fiona, and Darnell, Regna, 321. UBC Press.10.59962/9780774865234-002CrossRefGoogle Scholar
Gryseels, Charlotte, Kuijpers, Laura Maria Francisca, Jacobs, Jan, and Grietens, Koen Peeters. 2019. “When ‘Substandard’ Is the Standard, Who Decides What Is Appropriate? Exploring Healthcare Provision in Cambodia.” Critical Public Health 29 (4): 460–72. https://doi.org/10.1080/09581596.2019.1591614.CrossRefGoogle Scholar
Hart, Keith. 1973. “Informal Income Opportunities and Urban Employment in Ghana.” The Journal of Modern African Studies 11 (1): 6189.10.1017/S0022278X00008089CrossRefGoogle Scholar
Hayden, Cori. 2023. The Spectacular Generic. Pharmaceuticals and the Simipolitical in Mexico. Duke University Press. https://doi.org/10.1515/9781478023678.Google Scholar
Health Action International. 2023. “Informal Markets, and Substandard and Falsified Medical Products. A Scoping Review.” Unpublished Report. Accessed via personal communication.Google Scholar
Higgins, Vaughan, and Larner, Wendy. 2010. “Standards and Standardization as a Social Scientific Problem.” In Calculating the Social: Standards and the Reconfiguration of Governing, edited by Higgins, Vaughan and Larner, Wendy, 117. Palgrave Macmillan UK. https://doi.org/10.1057/9780230289673_1.CrossRefGoogle Scholar
Hughes, R., Chandler, C. R., Mangham-Jefferies, L. J., and Mbacham, W.. 2013. “Medicine Sellers’ Perspectives on Their Role in Providing Health Care in North-West Cameroon: A Qualitative Study.” Health Policy and Planning 28 (6): 636–46. https://doi.org/10.1093/heapol/czs103.CrossRefGoogle ScholarPubMed
Hutchinson, Eleanor, Hansen, Kristian Schultz, Sanyu, Jacquellyn, Amonya, Lydia Peace, Mundua, Sunday, Balabanova, Dina, Clarke, Sian E., and Kitutu, Freddy Eric. 2023. “Is it Possible for Drug Shops to Abide by the Formal Rules? The Structural Determinants of Community Medicine Sales in Uganda.” BMJ Global Health 8 (2): e011097. https://doi.org/10.1136/bmjgh-2022-011097.CrossRefGoogle ScholarPubMed
Hutchinson, Eleanor, Mundua, Sunday, Ochero, Lydia, Mbonye, Anthony, and Clarke, Sian E.. 2022. “Life in the Buffer Zone: Social Relations and Surplus Health Workers in Uganda’s Medicines Retail Sector.” Social Science & Medicine 300: 113941. https://doi.org/10.1016/j.socscimed.2021.113941.CrossRefGoogle ScholarPubMed
INEGI. 2025a. “Directorio Nacional de Unidades Económicas. DENUE.” Censos Económicos 2014, Instituto Nacional de Estadística y Geografía. INEGI. Accessed November 23, 2025. https://www.inegi.org.mx/app/mapa/denue/default.aspx.Google Scholar
INEGI. 2025b. “Estadísticas de Salud en Establecimientos Particulares (ESEP).” Reporte de Resultados No. 25/25. INEGI. https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2025/salud/ESEP2024_RR.pdf.Google Scholar
INEGI, and CANIFARMA. 2024. “Encuesta Nacional de la Industria Farmacéutica (ENIFARM) 2023.” Comunicado de Prensa No. 349/24. INEGI. https://inegi.org.mx/contenidos/saladeprensa/boletines/2024/ENIFARM/ENIFARM2023.pdf.Google Scholar
Institute for Health Metrics and Evaluation. n.d. “The Burden of Antimicrobial Resistance (AMR) in Mexico.” https://www.healthdata.org/sites/default/files/2023-09/Mexico.pdf.Google Scholar
Kamat, Vinay R., and Nyato, Daniel J.. 2010. “Soft Targets or Partners in Health? Retail Pharmacies and their Role in Tanzania’s Malaria Control Program.” Social Science & Medicine 71 (3): 626–33. https://doi.org/10.1016/j.socscimed.2010.04.016.CrossRefGoogle ScholarPubMed
Kamenshchikova, Alena, Fedotova, Marina M., Fedorova, Olga S., Fedosenko, Sergey V., Petra, F. G. Wolffs, Christian, J. P. A. Hoebe, and Horstman, Klasien. 2021. “Obligatory Medical Prescription of Antibiotics in Russia: Navigating Formal and Informal Health-Care Infrastructures.” Sociology of Health & Illness 43 (2): 353–68. https://doi.org/10.1111/1467-9566.13224.CrossRefGoogle ScholarPubMed
Kingori, Patricia, and Gerrets, René. 2019. “Why the Pseudo Matters to Global Health.” Critical Public Health 29 (4): 379–89. https://doi.org/10.1080/09581596.2019.1605155.CrossRefGoogle Scholar
Knaul, Felicia Marie, Arreola-Ornelas, Hector, Touchton, Michael, McDonald, T., Blofield, M., Avila Burgos, L., Gómez-Dantés, O., Kuri, P., Martinez-Valle, A., Méndez-Carniado, O., Nargund, R. S., Porteny, T., Sosa-Rubí, S. G., Serván-Mori, E., Symes, M., Vargas Enciso, V., and Frenk, J. 2023. “Setbacks in the Quest for Universal Health Coverage in Mexico: Polarised Politics, Policy Upheaval, and Pandemic Disruption.” The Lancet 402 (10403): 731–46. https://doi.org/10.1016/S0140-6736(23)00777-8.CrossRefGoogle ScholarPubMed
Koster, Martijn. 2019. “Assembling Formal and Informal Urban Governance: Political Brokerage in Recife, Brazil.” Anthropologica 61 (1): 2534. https://doi.org/10.3138/anth.2018-0014.CrossRefGoogle Scholar
Koster, Martijn, and Smart, Alan. 2019. “Performing in/Formality beyond the Dichotomy: An Introduction.” Anthropologica 61 (1): 2024. https://doi.org/10.3138/anth.2018-0013.CrossRefGoogle Scholar
Kumah, Emmanuel. 2022. “The Informal Healthcare Providers and Universal Health Coverage in Low and Middle-Income Countries.” Globalization and Health 18 (1): 45. https://doi.org/10.1186/s12992-022-00839-z.CrossRefGoogle ScholarPubMed
Kusenbach, Margarethe. 2003. “Street Phenomenology: The Go-along as Ethnographic Research Tool.” Ethnography 4 (3): 455–85. https://doi.org/10.1177/146613810343007.CrossRefGoogle Scholar
Lampland, Martha, and Star, Susan Leigh, eds. 2009. Standards and their Stories: How Quantifying, Classifying, and Formalizing Practices Shape Everyday Life. Cornell University Press.Google Scholar
Ledeneva, Alena. 2018. “Introduction: The Informal View of the World – Key Challenges and Main Findings of the Global Informality Project.” In The Global Encyclopaedia of Informality, Volume 1: Towards Understanding of Social and Cultural Complexity, edited by Ledeneva, Alena, Bailey, Anna, Barron, Sheelagh, Curro, Costanza, and Teague, Elizabeth, 127. UCL Press. https://doi.org/10.2307/j.ctt20krxh9.Google Scholar
Lomnitz, Larissa Adler. 1988. “Informal Exchange Networks in Formal Systems: A Theoretical Model.” American Anthropologist 90 (1): 4255. https://doi.org/10.1525/aa.1988.90.1.02a00030.CrossRefGoogle Scholar
López-Arellano, Oliva, and Delgado-Campos, Victoria Ixshel. 2024. “La transformación del Sistema público de Salud en la Ciudad de México.” Salud Pública de México 66 (5): 689–98. https://doi.org/10.21149/15659.CrossRefGoogle Scholar
Marcus, George E. 1995. “Ethnography in/of the World System: The Emergence of Multi-Sited Ethnography.” Annual Review of Anthropology 24 (1): 95117. https://doi.org/10.1146/annurev.an.24.100195.000523.CrossRefGoogle Scholar
McDermott, Joshua Lew. 2025. “Difference between Global South Cities: Mexico City, Freetown and the Global Division of Urban Informal Labour.” Urban Studies 62 (5): 932–53. https://doi.org/10.1177/00420980241269659.CrossRefGoogle Scholar
Evalúa, México. 2025. “Cambios En La Atención Pública de La Salud En México (2018–2024): Evidencia Desde La ENIGH y Perspectivas Comparadas.” México Evalúa. https://www.mexicoevalua.org/wp-content/uploads/2025/08/gasto-salud.pdf.Google Scholar
Mol, Annemarie. 2002. The Body Multiple. Duke University Press. https://doi.org/10.2307/j.ctv1220nc1.CrossRefGoogle Scholar
Nahar, Papreen, Unicomb, Leanne, Lucas, Patricia Jane, Uddin, Mohammad Rofi, Islam, Mohammad Aminul, Nizame, Fosiul Alam, Nirnita Khisa, S. M. Salim Akter, and Rousham, Emily K.. 2020. “What Contributes to Inappropriate Antibiotic Dispensing among Qualified and Unqualified Healthcare Providers in Bangladesh? A Qualitative Study.” BMC Health Services Research 20 (1): 656. https://doi.org/10.1186/s12913-020-05512-y.CrossRefGoogle ScholarPubMed
Nichter, Mark, and Vuckovic, Nancy. 1994. “Agenda for an Anthropology of Pharmaceutical Practice.” Social Science & Medicine 39 (11): 1509–25. https://doi.org/10.1016/0277-9536(94)90003-5.CrossRefGoogle ScholarPubMed
Nizame, Fosiul Alam, Shoaib, Dewan Muhammad, Rousham, Emily K., Akter, Salma, Islam, Mohammad Aminul, Khan, Afsana Alamgir, Rahman, Mahbubur, and Unicomb, Leanne. 2021. “Barriers and Facilitators to Adherence to National Drug Policies on Antibiotic Prescribing and Dispensing in Bangladesh.” Journal of Pharmaceutical Policy and Practice 14 (S1): 85. https://doi.org/10.1186/s40545-021-00342-7.CrossRefGoogle ScholarPubMed
NMás. 2020. “Venta Ilegal de Medicamentos En Tianguis de La CDMX - Despierta.” Youtube Video 4: 33. https://www.youtube.com/watch?v=sQkwKzgNh_8.Google Scholar
NMás. 2023. “Venta de Medicamentos Falsos En Tianguis - En Punto.” Youtube Video 02: 19. https://www.youtube.com/watch?v=K2h9sDmKVEg.Google Scholar
Osorio, Carranza, María, Rosa. 2020. “Consultation Rooms Annexed to Pharmacies: The Mexican Private, Low-Cost Healthcare System.” In Critical Medical Anthropology, edited by Gamlin, Jennie, Gibbon, Sahra, Sesia, Paola M., and Berrio, Lina, 195221. UCL Press. https://doi.org/10.2307/j.ctv13xprxf.15.CrossRefGoogle Scholar
Oga-Omenka, Charity, Okafor, Ukamaka, and Sulis, Giorgia. 2023. “Engaging Pharmacists and Medicine Vendors in Antimicrobial Stewardship in LMICs.” The Lancet Infectious Diseases 23 (7): 786–87. https://doi.org/10.1016/S1473-3099(23)00342-0.CrossRefGoogle ScholarPubMed
Pérez-Cuevas, Ricardo, Doubova, Svetlana V., Wirtz, Veronika J., Servan-Mori, Edson, Dreser, Anahí, and Hernández-Ávila, Mauricio. 2014. “Effects of the Expansion of Doctors’ Offices Adjacent to Private Pharmacies in Mexico: Secondary Data Analysis of a National Survey.” BMJ Open 4 (5): e004669. https://doi.org/10.1136/bmjopen-2013-004669.CrossRefGoogle ScholarPubMed
Portes, Alejandro, and Haller, William. 2005. “The Informal Economy.” In The Handbook of Economic Sociology, Second Edition, edited by Smelser, Neil J. and Swedberg, Richard, 403–26. Princeton University Press. http://www.jstor.org/stable/j.ctt2tt8hg.22.Google Scholar
Rangel-Gutiérrez, Rodrigo. Forthcoming. “‘They Made Like They Inspected’: Irregular Regulation in Mexico City’s Pharmaceutical Supply Chain.”Google Scholar
Reich, Michael R. 2020. “Restructuring Health Reform, Mexican Style.” Health Systems & Reform 6 (1): e1763114. https://doi.org/10.1080/23288604.2020.1763114.CrossRefGoogle ScholarPubMed
Rodrigues, Carla F. 2020. “Self-Medication with Antibiotics in Maputo, Mozambique: Practices, Rationales and Relationships.” Palgrave Communications 6 (1): 6. https://doi.org/10.1057/s41599-019-0385-8.CrossRefGoogle Scholar
Rodríguez, Alejandra. 2023. “De Mal En Peor: Sube 92% Mercado Negro de Medicinas Durante Sexenio de AMLO.” El Financiero, August 16. https://www.elfinanciero.com.mx/empresas/2023/08/16/de-mal-en-peor-sube-92-mercado-negro-de-medicinas-durante-sexenio-de-amlo/.Google Scholar
Scott, James C. 1998. Seeing like a State. How Certain Schemes to Improve the Human Condition Have Failed . Yale University Press.Google Scholar
Secretaría de Salud. 1984. “Ley General de Salud. Diario Oficial de la Federación.” https://www.diputados.gob.mx/LeyesBiblio/pdf/LGS.pdf.Google Scholar
Serván-Mori, Edson, Gómez-Dantés, Octavio, Contreras, David, Flamand, Laura, Cerecero-García, Diego, Arreola-Ornelas, Héctor, and Knaul, Felicia M.. 2023. “Increase of Catastrophic and Impoverishing Health Expenditures in Mexico Associated to Policy Changes and the COVID-19 Pandemic.” Journal of Global Health 13: 06044. https://doi.org/10.7189/jogh.13.06044.CrossRefGoogle ScholarPubMed
Shore, Cris, and Wright, Susan. 2015. “Audit Culture Revisited: Rankings, Ratings, and the Reassembling of Society.” Current Anthropology 56 (3): 421–44. https://doi.org/10.1086/681534.CrossRefGoogle Scholar
Smith, Daniel Jordan. 2007. “Introduction.” In A Culture of Corruption: Everyday Deception and Popular Discontent in Nigeria, 127. Princeton University Press.Google Scholar
Soniran, Olajoju Temidayo, Mensah, Benedicta Ayiedu, Cheng, Ndong Ignatius, Abuaku, Benjamin, and Ahorlu, Collins Stephen. 2022. “Improved Adherence to Test, Treat, and Track (T3) Malaria Strategy among Over-the-Counter Medicine Sellers (OTCMS) through Interventions Implemented in Selected Rural Communities of Fanteakwa North District, Ghana.” Malaria Journal 21 (1): 317. https://doi.org/10.1186/s12936-022-04338-9.CrossRefGoogle Scholar
Steenberg, Rune. 2016. “The Art of Not Seeing like a State. On the Ideology of ‘Informality.’Journal of Contemporary Central and Eastern Europe 24 (3): 293306. https://doi.org/10.1080/0965156X.2016.1262229.CrossRefGoogle Scholar
Sudhinaraset, May, Ingram, Matthew, Lofthouse, Heather Kinlaw, and Montagu, Dominic. 2013. “What Is the Role of Informal Healthcare Providers in Developing Countries? A Systematic Review.” PLoS One 8 (2): e54978. https://doi.org/10.1371/journal.pone.0054978.CrossRefGoogle Scholar
Suy, Sovanthida, Rego, Sonia, Bory, Sothavireak, Chhorn, Sophea, Phou, Socheata, Prien, Chanra, Heng, Sotheara, Wu, S., Legido-Quigley, H., Hanefeld, J., Saphonn, V., and Khan, M. S.. 2019. “Invisible Medicine Sellers and their Use of Antibiotics: A Qualitative Study in Cambodia.” BMJ Global Health 4 (5): e001787. https://doi.org/10.1136/bmjgh-2019-001787.CrossRefGoogle ScholarPubMed
Suzuki, Wakana. 2021. “Improvising Care: Managing Experimental Animals at a Japanese Laboratory.” Social Studies of Science 51 (5): 729–49. https://doi.org/10.1177/03063127211010223.CrossRefGoogle Scholar
Svarch, Alejandro E., Rosales, Miriam Jackeline Loera, Contreras, Arlet Veloz, Lugo, Holjes Salgado, Vázquez, Liliana Esmeralda Reyes, and Sandoval, Rosa Camacho. 2024. “Actions to Combat Antimicrobial Resistance in Mexico: A Perspective from COFEPRIS.” Revista Mexicana de Política Exterior 129: 7386.Google Scholar
Tandan, Meera, Thapa, Poshan, Bhandari, Buna, Gandra, Sumanth, Timalsina, Diwash, Bohora, Shweta, Thapaliya, Swostika, Bhusal, A., Gore, G.C., Sheokand, S., Shukla, P., Joshi, C., Mudgal, N., Pai, M., and Sulis, G.. 2024. “Antibiotic Dispensing Practices among Informal Healthcare Providers in Low-Income and Middle-Income Countries: A Scoping Review Protocol.” BMJ Open 14 (6): e086164. https://doi.org/10.1136/bmjopen-2024-086164.CrossRefGoogle ScholarPubMed
Tillmann-Healy, Lisa M. 2003. “Friendship as Method.” Qualitative Inquiry 9 (5): 729–49. https://doi.org/10.1177/1077800403254894.CrossRefGoogle Scholar
Timmermans, Stefan, and Epstein, Steven. 2010. “A World of Standards but Not a Standard World: Toward a Sociology of Standards and Standardization.” Annual Review of Sociology 36 (1): 6989. https://doi.org/10.1146/annurev.soc.012809.102629.CrossRefGoogle Scholar
van der Geest, Sjaak. 1985. “The Intertwining of Formal and Informal Medicine Distribution in South Cameroon.” Canadian Journal of African Studies / Revue Canadienne Des Études Africaines 19 (3): 569–87. https://doi.org/10.1080/00083968.1985.10804132.CrossRefGoogle Scholar
Varadan, Sheila Rose, Chandler, Clare Isobel Rosina, Weed, Kym, Ahmed, Syed Masud, Atuire, Caesar, Batheja, Deepshikha, Bull, Susan Jane, et al. 2023. “A Just Transition for Antimicrobial Resistance: Planning for an Equitable and Sustainable Future with Antimicrobial Resistance.” The Lancet. https://doi.org/10.1016/S0140-6736(23)01687-2.Google Scholar
Vega, Andrea. 2022. “Desabasto de Medicamentos y Falta de Atención En Las Instituciones Incrementa Hasta 40% El Gasto de Bolsillo En Salud.” Animal Político, March 3. https://animalpolitico.com/sociedad/desabasto-medicamentos-atencion-gasto-bolsillo-salud.Google Scholar
Will, Catherine M. 2020. “The Problem and the Productivity of Ignorance: Public Health Campaigns on Antibiotic Stewardship.” The Sociological Review 68 (1): 5576. https://doi.org/10.1177/0038026119887330.CrossRefGoogle Scholar
Willis, Denyer, Laurie, Miriam Kayendeke, and Chandler, Clare I. R.. 2023. “The Politics of Irrationality.” Medical Anthropology Quarterly 37 (4): 382–95. https://doi.org/10.1111/maq.12809.CrossRefGoogle Scholar
Figure 0

Figure 1. Marcelo’s customer service decalogue. Digital photo by RRG, unlicensed pharmacy in the outskirts of Mexico City, April 16, 2024.

Figure 1

Figure 2. Box with the legend Antibiotics of Mexico, the name of a generic medicines company, on top of sacks of potatoes. Digital photo by RRG, La Merced market in Mexico City, June 6, 2025.

Figure 2

Figure 3. A freshly used syringe and the packaging of a ceftriaxone vial on Gloria’s table. Digital photo by RRG, La Merced market in Mexico City, February 24, 2024.

Figure 3

Figure 4. The antibiotics section of the medicine-and-potato stall. The second and third levels from the top down are mostly filled with ceftriaxone ampules. Digital photo by RRG, La Merced market in Mexico City, April 12, 2024.